
==== Front
Microorganisms
Microorganisms
microorganisms
Microorganisms
2076-2607
MDPI

10.3390/microorganisms9071509
microorganisms-09-01509
Article
Predicted Cellular Interactors of the Endogenous Retrovirus-K Integrase Enzyme
Benoit Ilena 1†
Brownell Signy 1†
https://orcid.org/0000-0002-7854-007X
Douville Renée N. 12*
Staege Martin S. Academic Editor
Emmer Alexander Academic Editor
1 Department of Biology, University of Winnipeg, 599 Portage Avenue, Winnipeg, MB R3B 2G3, Canada; benoit-i@webmail.uwinnipeg.ca (I.B.); brownell-s@webmail.uwinnipeg.ca (S.B.)
2 Department of Immunology, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB R3E 0T5, Canada
* Correspondence: r.douville@uwinnipeg.ca
† These authors contributed equally to this work.

14 7 2021
7 2021
9 7 150916 6 2021
09 7 2021
© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Integrase (IN) enzymes are found in all retroviruses and are crucial in the retroviral integration process. Many studies have revealed how exogenous IN enzymes, such as the human immunodeficiency virus (HIV) IN, contribute to altered cellular function. However, the same consideration has not been given to viral IN originating from symbionts within our own DNA. Endogenous retrovirus-K (ERVK) is pathologically associated with neurological and inflammatory diseases along with several cancers. The ERVK IN interactome is unknown, and the question of how conserved the ERVK IN protein–protein interaction motifs are as compared to other retroviral integrases is addressed in this paper. The ERVK IN protein sequence was analyzed using the Eukaryotic Linear Motif (ELM) database, and the results are compared to ELMs of other betaretroviral INs and similar eukaryotic INs. A list of putative ERVK IN cellular protein interactors was curated from the ELM list and submitted for STRING analysis to generate an ERVK IN interactome. KEGG analysis was used to identify key pathways potentially influenced by ERVK IN. It was determined that the ERVK IN potentially interacts with cellular proteins involved in the DNA damage response (DDR), cell cycle, immunity, inflammation, cell signaling, selective autophagy, and intracellular trafficking. The most prominent pathway identified was viral carcinogenesis, in addition to select cancers, neurological diseases, and diabetic complications. This potentiates the role of ERVK IN in these pathologies via protein–protein interactions facilitating alterations in key disease pathways.

endogenous retrovirus
integrase
interactome
eukaryotic linear motif
DNA damage response
viral carcinogenesis
cancer
amyotrophic lateral sclerosis
diabetes
model organisms
==== Body
1. Introduction

Viral proteins often usurp and alter cellular signaling pathways. For exogenous viruses, this tweaking of cellular function serves to enhance their replicative success through the modulation of pathways related to virion production, dissemination, cell survival, and immunity [1,2]. It is less clear in what manner ever-present viral symbionts such as endogenous retroviruses (ERVs) interact with the proteome of their hosts.

The genomes of eukaryotic organisms are widely populated with ERVs [3,4,5]. Endogenous retrovirus-K (ERVK/HERV-K) is a biomedically-relevant symbiont within the primate lineage [6,7]. Its expression has been associated with a variety of cancers [8], neurological conditions [9,10,11,12,13], autoimmune diseases [14], and infections [13,15]. A common thread that weaves through ERVK-associated disease is genomic instability. DNA damage and genomic alterations are hallmarks of many cancers [16], as well as in the neurons of patients with the motor neuron disease ALS [17,18]. One protein known to cause DNA damage during the retroviral life cycle is the integrase (IN) enzyme [19]. Recovery from IN-driven lesions is reliant on the host DNA damage response (DDR) [20,21].

We have previously shown that several ERVK insertions in the human genome have the potential to produce functional ERVK IN enzymes with the identical DDE active site motif found in human immunodeficiency virus (HIV) IN [22]. Based on homology modeling, we predict that the ERVK IN enzyme contains all the essential motifs and domain structures for retroviral IN function [22]. A recombinant ERVK-10 integrase enzyme also confirms that it has the potential for strand-transfer activity [23]. A remaining question is how ERVK IN interacts with cellular proteins and pathways, as has been shown for many other retroviral integrases [19,24,25,26].

Retroviral INs are involved in pre-integration complex (PIC) transport [27], viral genome integration into host DNA [19], and virion maturation [28]. Thus, retroviral integrase enzymes exhibit a diversity of cellular partners and have been shown to impact cell signaling and survival processes, including the DDR [19,29]. For example, retroviral IN often recruits viral proteins (reverse transcriptase, matrix, and capsid) and cellular factors (BANF1, HGMA1, LEDGF) to participate in the viral DNA integration process [30,31]. Moreover, successful viral DNA integration requires engagement of the host DDR proteins to repair residual single-stranded DNA gaps flanking the integration site [20,29,32]. In contrast, failed provirus insertion or unresolved lesions can lead to double-stranded DNA (dsDNA) breaks in the host genome [29]. The level of γH2AX foci is positively correlated with the number of double-stranded DNA breaks (DSB) in mammalian cells, and it is widely used as a quantitative biomarker of retrovirus-mediated DSBs [19,33,34]. This genomic damage is particularly hazardous to the cell, as DSB potentially lead to chromosomal rearrangements, cellular deregulation, and apoptosis [35,36]. Thus, as an intrinsic protective measure, select host proteins (RAD51, Kap1, TREX1, p21, HDAC10, TRIM33) are known antagonists of the retroviral integration process [31,37,38,39,40]. Many studies have identified direct protein binding partners and cellular complexes which interact with HIV integrase [41,42,43]; in contrast, the ERVK IN interactome remains unknown.

A complicating factor for the development of model systems to study the impact of ERVK proteins in vivo is that many other organisms contain ERVs with similarity to ERVK. Given the known cellular impacts of retroviral integrases, we hypothesized that a computational biology approach would identify potential cellular partners of ERVK IN and point toward its capacity to modulate cellular pathways. Additionally, a comparison with similar integrases in eukaryotic organism and model species may inform the future establishment of in vivo models for ERVK IN-driven pathology.

2. Materials and Methods

2.1. Database Curation

Integrases with sequence similarity to ERVK IN (based on ERVK-10 [22]; P10266.2) were identified using the National Centre for Biotechnology’s (NCBI) Protein–protein Basic Local Alignment Search Tool (BLASTp) within the non-redundant (nr), model organisms (mo), and transcriptome shotgun assembly proteins (tsa) databases [44]. Default algorithm parameters were used, with E-value cut-offs for each database as follows: E < 3.0 × 10−70 (nr), E < 0.01 (mo), E < 2.0 × 10−10 (tsa). Sequences were grouped based on phylogeny as informed by ICTV (International Committee on Taxonomy of Viruses; 2021, https://talk.ictvonline.org/ (accessed on 16 May 2021)) or OneZoom (OneZoom Tree of Life Explorer; version 3.4.1; Software for Technical Computation; United Kingdom, 2021, https://www.onezoom.org/ (accessed on 16 May 2021)) [45] and are listed in Table A1, Table A2, Table A3 and Table A4.

2.2. Protein Alignments and Eukaryotic Linear Motif Annotation

The ERVK IN protein sequence, as well as select representative integrases from exogenous Betaretroviruses (Figure 1) or endogenous retroviruses (Figure 2) were aligned using Geneious Prime (version 2021.0.3; Software for Technical Computation; San Diego, CA, USA; Auckland, New Zealand, 2021) software [46]. A global alignment with free end gaps using BLOSUM62 matrix was performed. Longer sequences were truncated to overlap with the ERVK IN reference sequence. Figures depict the sequence logo and integrase active sites, with HHCC and DDE regions highlighted based on Conserved Domains Database (CDD) annotation [47].

Each aligned integrase sequence was submitted to the Eukaryotic Linear Motif (ELM; Software for Technical Computation; 2020, http://elm.eu.org/ (accessed on 16 May 2021)) resource [48]. A complete listing of ELMs identified in each integrase is presented in Table 1 and Table 2. ELMs unique to ERVK IN, as well as ELM sites exhibiting motif consensus above 70% with other integrases, were annotated in Figure 1 and Figure 2.

2.3. STRING Analysis and KEGG Pathways

To identify potential ERVK IN binding partners based on ELM motifs, the names of interacting proteins were curated from each ELM reference page. When only a general interaction domain for a given ELM was listed, it was further linked to the InterPro database to curate a list of human proteins containing the interaction domain. Based on the 48 ELMs identified in ERVK IN, a total of 213 putative human protein interaction partners were identified (Table A5). The list was submitted to STRING (String Consortium; version 11.0; Software for Technical Computation; 2020, https://string-db.org/, accessed on 16 May 2021) for network analysis. Full network analysis was performed using Experiment and Databases as active interaction sources. Nodes indicate submitted query proteins only, with edges indicating confidence lines with a minimum interaction score of 0.9 (highest confidence). Query proteins unlinked to the network were excluded from analysis. A payload list was used to color hub proteins based on cellular function. KEGG pathways associated with the network analysis (E value < 1.0 × 10−5) were presented in a heatmap using GraphPad Prism (version 9.1.1) software, and the full list of KEGG pathways is presented in Table A6.

3. Results

3.1. Characterization of Eukaryotic Linear Motifs in ERVK Integrase and Other Betaretroviral Integrases

To establish which exogenous and endogenous retroviruses contain integrase sequences most similar to ERVK IN, we performed BLASTp searches using the nr, mo, and tsa NCIB databases. As expected, exogenous Betaretroviruses were identified through BLASPp search, which included multiple hits for Mouse mammary tumor virus (MMTV), Mason–Pfizer monkey virus (M-PMV), Enzootic Nasal Tumor Virus (ENTV), and Jaagsiekte sheep retrovirus (JSRV) (Table A1).

Eukaryotic linear motif (ELM) analysis of a representative sequence from each genus was compared with ERVK IN and revealed the conservation of select protein motifs (Table 1, Figure 1). Apart from the conservation of the HHCC region and DDE active site motif, all betaretroviral integrases also contained many interaction motifs related to DRR, including Pin1 via [ST]P WW domain interaction motifs [49], PP1c docking motif for target dephosphorylation [50], and a S-X-X-S/T CK1 phosphorylation site [51]. All INs except for MMTV contained a low-affinity BRCA1 carboxy-terminal BRCT domain binding motif (CSKAF, aa. 126–132). Betaretroviral INs were also predicted to be phosphorylated by the cell cycle checkpoint kinases NEK2 [52] and PLK-1 [53], as well as interact with a canonical arginine-containing phospho-motif within cell cycle regulating 14-3-3 proteins [54]. Numerous cell signaling protein interactions were predicted including YXXQ motifs for the SH2 domain binding of STAT3 [55], additional SH2 binding motifs related to STAT5 [56] and SRC family kinases [57], SH3 binding motifs with non-canonical class I recognition specificity [58], an IAP-binding motif (aa. 1–4) for interaction with inhibitor of apoptosis proteins (IAP) [59], an ITIM motif [60], several GSK3 phosphorylation sites [61], and proline-directed ERK/p38 MAPK phosphorylation sites [62]. In addition, most betaretroviral IN enzymes contained features related to protein trafficking, such as a Wxxx[FY] motif (aa. 133–137 in ERVK, MMTV, ENTV, and JRSV) that binds Pex13 and Pex14 for peroxisomal import [63], a SxIP motif (aa. 137–150) that binds to EBH domains in end-binding proteins involved in microtubule transport [64], and a tyrosine-based YXXØ sorting signal (aa. 75–78) for interaction with the μ-subunit of adaptor protein complex [65] and a PEXEL-like motif [66]. The DDE region displayed the most consistent pattern of conserved ELMs among the betaretroviral INs. It is important to note that despite the similar complement of ELM motifs in betaretroviral integrases, many were positioned at sites differently than in ERVK IN. Additional ELMs and their motif frequencies in individual betaretroviral integrases are listed in Table 1.

3.2. Characterization of Eukaryotic Linear Motifs in ERVK Integrase and Other Endogenous Integrases

ERVK integrase-like sequences were found in boreoeutherians, including the Euarchontoglires (primates, rodents, and pikas), and Laurasiatherians (ungulates), along with other clades including Euteleostomi (birds) and Protostomes (worms, insects, and water fleas) (Table A2, Table A3 and Table A4). Results ranged from 26.43 to 83.77% identity and E values ranged from 0.001 to 2.0 × 10−127, demonstrating a high degree of similarity with ERVK IN.

The conservation of ELM motifs was apparent (Table 2, Figure 2), including DDR-related canonical 14-3-3 interaction motifs and WDR5 interaction, cell signaling associated with USP7 binding, IAP-binding motif, STAT5 binding motifs, SH3 protein interaction, as well as phosphorylation sites for CK proteins, GSK3, NEK2, polo-like kinases, and p38. Many LIR motifs for engaging Atg8 proteins during selective autophagy were also apparent. Finally, all IN displayed Pex14 binding motifs and potential to interact with the μ-subunit of the adaptor protein complex. Additional ELMs and their motif frequencies in individual endogenous ERVK-like INs are listed in Table 2.

ELMs within endogenous IN but not or rarely identified in ERVK IN were also noted. An Apicomplexa-specific variant of the canonical LIR motif that binds to Atg8 protein family members was present in all endogenous INs except for ERVK IN. In addition, WDR5 binding motifs were much more prevalent in endogenous INs (5–12 sites) other than ERVK IN (only two sites). ERVK IN contained a single MAPK docking site for ERK/p38, whereas other endogenous INs contained several other motifs for MAPK interaction. Lastly, only human and macaque ERVK INs displayed high-affinity BRCT domain interaction motifs.

3.3. Unlike Similar Enzymes, the ERVK Integrase Contains Distinct ELM Signatures

Two motifs in ERVK IN stand out as unique to this virus, while other signatures are enriched in ERVK IN as compared with similar integrases.

3.3.1. ERVK Integrase has a High-Affinity BRCA1 Binding Site

Among all the integrases examined, only ERVK IN in human and macaque harbored a high-affinity binding site for the BRCT domain of BRCA1 (aa. 125–131, CSKAFQK) (Table 1 and Table 2, Figure 1 and Figure 2).

3.3.2. ERVK Integrase C-Terminus Contains a 14-3-3 Binding RASTE Motif

Although 14-3-3 protein binding was predicted as conserved among ERVK-like integrases, only ERVK IN contained a C-terminal RASTE motif (aa. 276–280) mediating strong interaction with 14-3-3 proteins (Table 1, Figure 1). This suggests a putative ERVK IN interaction with 14-3-3 proteins through both canonical phospho-sites and a C-terminal phospho-site.

3.3.3. ERVK Integrase Is Likely Post-Translationally Sumoylated

Unlike all other INs examined, only ERVK and MMTV contain a C-terminal inverted version (D/ExKphi) of the canonical sumoylation motif [67]. Considering that sumoylation often causes re-localization of nuclear proteins, this modification may be related to ERVK IN nuclear positioning, association with chromatin, and ultimately successful integration of viral DNA [68,69].

3.3.4. ERVK Integrase Exhibits Enhanced Interaction Potential with DDR Proteins

Phospho-Ser/Thr binding domain proteins are key hub proteins in cell cycle regulation and DDR, and they include 14-3-3 proteins, WW domains, Polo-box domains, WD40 repeats, BRCA1 carboxy-terminal (BRCT) domains, and Forkhead-associated (FHA) domains [54], all of which are interacting domains of ELMs identified in ERVK IN (Table 1 and Table 2, Figure 1). Additionally, ERVK IN contained five (ST)Q motifs, which are potential phosphorylation sites for PIKK proteins, such as DDR-related proteins ATR, ATM, DNA-PK, and multi-functional protein mTOR [70]. As compared with exogenous betaretroviruses and endogenous ERVK-like integrases, ERVK IN displayed a greater number of DDR-related motifs: FHA domain protein interaction sites (6), PLK-1 phosphorylation sites (4), and PP1c docking motif for target dephosphorylation (3) [50]. In contrast to MMTV, ENTV, JSRV, and most other endogenous integrases, fewer WD40 repeat domain WDR5 interaction sites were found in ERVK IN (2 vs. 5–12 sites each). This suggests ERVK IN has potentially shifted away from WDR5 interaction in favor of BRCA1 (or BRCT domain) interaction as a means to interact with the DDR pathway [54,71].

3.3.5. ERVK Integrase Contains Canonical Selective Autophagy Motifs

Unlike any of the exogenous betaretroviruses, only ERVK IN and some endogenous integrases contained canonical LIR motifs (ELME000368) for binding Atg8 protein family members (Table 1 and Table 2, Figure 2). All endogenous INs contained nematode-specific LIR motifs (ELME000370). Additionally, most endogenous INs housed Apicomplexa-specific LIR motifs (ELME000369), whereas ERVK IN did not.

3.4. ERVK Interactome Reveals Association with a Diversity of Cellular Pathways

Based on ELMs identified in ERVK IN, a curated list of potential interacting proteins was generated and used to build an ERVK IN interactome network using STRING software (Figure 3). The ERVK IN network contained 189 nodes and 692 edges (expected number of edges 222), resulting in a significant PPI enrichment (p < 1.0 × 10−16). Only direct interactor query proteins are shown without links to second shell interactions. To illustrate key nodes and hub proteins, select network proteins were colored based on function related to DDR, cell cycle, apoptosis, cell signaling, or cellular transport. A complete list of the KEGG pathways significantly associated with the network is presented in Table A6.

3.4.1. Many DNA Damage Response Proteins Are Potential ERVK Integrase Interactors

Gene ontology (GO) biological processes that were significantly enriched in the network included cellular response to DNA damage stimulus (p < 4.4 × 10−18), DNA repair (p < 4.24 × 10−12), DNA damage checkpoint (p < 4.89 × 10−12), double-strand break repair via non-homologous end joining (NHEJ) (p < 3.57 × 10−9), double-strand break repair (p < 1.06 × 10−8), and signal transduction in response to DNA damage (p < 2.12 × 10−8). Select BRCT domain containing proteins emerged as nodes with a higher-than-average degree of connections, including BRCA1, BARD1, NBN, MDC1, RCF1, TOPBP1, TP53BP1, and PAXIP1, while PARP1 and DRKDC (DNA-PK) appear to be hub proteins between DDR and apoptosis. The ERVK IN network also displayed four prominent DDR-related FHA proteins: CHEK2, NBN, MDC1, and RNF8.

3.4.2. ERVK Integrase Likely Modulates Cell Cycle Pathways

GO biological processes that were significantly enriched in the network included regulation of cell cycle (p < 1.45 × 10−33), cell division (p < 1.12 × 10−20), regulation of cyclin-dependent serine/threonine kinase activity (p < 6.86 × 10−20), mitotic cell cycle (p < 2.78 × 10−17), regulation of apoptotic process (p < 1.45 × 10−17), and cell cycle checkpoint (p < 6.72 × 10−12). Many cyclins and 14-3-3 proteins were identified in the network and are listed in Table A5. IAP-containing protein BIRC5 (also known as survivin) was also identified, which is suggestive of negative regulation of programmed cell death pathways [72]. PLK1 and NEK2 were also tied into the cell cycle framework and are both regulators of mitosis, in addition to displaying oncogenic properties [73,74].

3.4.3. Cell Signaling Pathways Associated with the ERVK Interactome

Among the potential signaling pathways often targeted by retroviruses, ERVK IN-associated cascades emerged as Forkhead box O (FoxO) signaling [75], p53 signaling [76], ErbB signaling [77], Wnt signaling [78], modulation of kinase activity [79,80], and multiple aspects of immune signaling [81] (Figure 4). Within these pathways, prominent immune-related signaling intermediates included STAT3 [55], STAT5 [56], and TRAF2 [82]. The SH2 and SH3 containing tyrosine-protein kinase ABL1 (Abelson murine leukemia viral oncogene homolog 1 [57]) appears to be a key hub protein linking DDR and downstream signaling cascades.

3.4.4. ERVK Integrase May Utilize Specific Cellular Transport Systems

The ERVK interactome contains proteins related to cellular transport. EB1 (MAPRE1) is an end-binding (EB) protein connected with both cell cycle and signaling pathways and is functionally associated with the regulation of microtubule dynamics [83]. Adaptor protein complex 2 associated proteins (AP2M1 and CTTN) were identified and indicate a role in cargo internalization via clathrin-mediated endocytosis and actin dynamics [65,84]. Lastly, ERVK IN may interact with Pex14 and Pex13 independently of the main network for peroxisome import [63]. While these pathways were likely important for the ancestral exogenous ERVK to transverse the cell and mediate infection, it remains unclear how endogenous IN may interact with these systems.

3.5. Diseases and Pathways Implicated in the ERVK Integrase Interactome

3.5.1. Cancers

Viral carcinogenesis was the top KEGG pathway identified in the ERVK IN network analysis (strength 1.22, E value 3.7 × 10−23), with 29 of 183 proteins represented (Figure 4). KEGG pathways for several known ERVK-associated cancers were also identified, including lung cancer [85], myeloid leukemia [86], and hepatocellular carcinoma [87] (Figure 4). Glioma was also identified, yet ERVK is downregulated in this condition [88]. Aligned with cellular transformation, proteins associated with cell cycle were also over-represented in the pathway analysis, which are specifically related to the cyclin docking site ELM (DOC_CYCLIN_RxL_1) and numerous FHA domain protein interaction sites (LIG_FHA_1 and LIG_FHA_2) in ERVK IN (Table 1 and Table 2, Figure 1 and Figure 2).

3.5.2. Neurological Disease

KEGG pathways for several ERVK-associated neurological conditions were identified, including ALS [9,12], Alzheimer’s disease [89], and prion disease [90] (Figure 4). Specifically, long-term potentiation and synaptic neurotransmitter release (dopaminergic, glutamatergic, cholinergic, serotonergic, and GABAergic) were associated with the ERVK IN interactome.

3.5.3. Diabetes

The role of ERVK in diabetes remains contentious [91,92,93,94]. However, network analysis suggests that the ERVK IN interactome is potentially linked to AGE-RAGE signaling in diabetic complications, insulin signaling, and insulin resistance (Figure 4).

4. Discussion

ERVK expression has been repeatedly associated with human disease states including cancer, neurological disease, and diabetes. By exploring the potential ERVK integrase interactome, we can postulate how this viral symbiont may contribute to disease pathogenesis via interaction with key proteins and pathways. Our analysis reveals that viral carcinogenesis and modulation of the DNA damage response are the most likely pathways to be pathologically associated with ERVK IN expression.

Retroviral integrase activity causes DNA lesions in the host genome as part of the proviral integration process [19]; therefore, interactions with DDR pathways are to be expected. Several DDR proteins have been shown to be essential for provirus suture into the host genome and maintenance of genome fidelity [19]. Yet, the impairment of select aspects of DDR has also been documented in exogenous retroviral infections, including HIV [95,96] and HTLV-1 [97,98]. This may be driven by the fact that NHEJ proteins also play an essential role in innate immune recognition of retroviral cytosolic ssDNA intermediates and dsDNA pre-integration complexes [98,99]. Thus, retroviruses must balance the benefits and drawbacks of DDR outcomes through the engagement and modulation of specific proteins.

BRCT domain, FHA domain, and 14-3-3 proteins work in concert during the DNA damage response (reviewed in [100]). Many of these DDR proteins are also cellular targets of retroviruses and oncogenic viruses [98,101,102,103,104]. BRCA1 BRCT domains recognize phosphopeptides based on a pSXXF motif, but XX residues and the surrounding amino acids also impact binding affinity and selectivity [105]. All the betaretroviral INs examined showed the capacity to interact with BRCT domains. However, only ERVK IN displayed a high affinity (S.F.K) BRCA1 BRCT domain binding site; the only other similar ELM structure is found in the DDR protein Fanconi anemia group J protein (FACJ/BACH1) [106]. It is also possible that dual anchoring onto the ERVK IN using both a BRCT domain and an FHA domain found in NBN or MDC1 may strengthen protein–protein interactions.

The utilization and evasion of 14-3-3 proteins are common among many viruses [104]. ERVK IN is unique in having a C-terminal RASTE motif, in addition to two other canonical arginine containing phospho-motifs recognized by 14-3-3 proteins. Given that an elevated expression of 14-3-3 proteins occurs in both cancers and neurodegenerative diseases [107,108], ERVK IN interaction with 14-3-3 protein members may be related to either modulation of the cell cycle and oncogenesis or regulation of protein aggregation, respectively. The deregulation of 14-3-3 and RAF kinase interaction can also lead to inappropriate downstream MAPK activity (associated with oncogenesis) [54,109] and may be an aspect to consider for the predicted ERVK IN network.

ABL1 appears to be a key hub protein linking DDR and downstream signaling cascades. Interestingly, DDR is known to be a rapid driver of ABL1 activation [110]. The ablation of ABL1 reduces retrovirus integration [111,112], while active ABL1 can turn on the HIV promoter independently of HIV Tat [113]. Putative interaction between ERVK IN and ABL1 may have been important for ERVK integration into germline cells, and it may additionally play a role in ERVK expression, specifically in neurodegenerative disease displaying enhanced ABL1 activity [114,115].

DDR is intimately tied to innate immune response, specifically NF-κB activation [116]. Considering ERVK’s dependence on NF-κB for driving its own expression [11], it is conceivable that ERVK IN plays a role in preparing the host cell for viral transcription. 14-3-3ϵ activity is key in driving ATM-TAK1-mediated NF-κB signaling during DDR [117,118]; thus, the predicted ERVK IN interaction with 14-3-3ϵ (YWHAE) may be a mechanism to favor viral transcription. The MAPK p38 was also predicted to both phosphorylate and bind ERVK IN. This association may be linked to p38′s regulation of inflammatory signaling, as well as its capacity to enhance the transcriptional activity of NF-κB p65 via modulation of the acetyltransferase activity of coactivator p300 [119]. Sustained NF-κB activity is linked to oncogenesis [116] and ties into the strongest ERVK IN-linked KEGG pathway: viral carcinogenesis. However, enhanced ERVK IN-associated NF-κB signaling may also fit with inflammatory and neurodegenerative conditions.

ERVK IN stability and protein turnover is likely linked to its cellular protein partnerships. In the case of HIV, binding select cellular proteins such as LEDGF/p75 and Ku70 prevents integrase proteosomal degradation [120,121]. Similarly, c-Jun N-terminal kinase (JNK) S57 phosphorylation of the core domain can make HIV IN a target for Pin1, thus enhancing its stability and activity [122,123]. In this study, Pin1′s WW domain was predicted to be an interactor based on three [ST]P motifs in the C-terminal portion of ERVK IN. This raises the possibility that similar to many other viral proteins [124], ERVK IN may be stabilized through Pin1 interaction. The functional significance of this interaction may underlie how elevated levels of ERVK IN are maintained and potentially drive pathology in select diseases, such as ALS and cancer.

Distinct from other exogenous betaretroviruses, only ERVK IN and some endogenous integrases contained canonical LIR motifs for binding Atg8 protein family members. Mammalian Atg8-like proteins include LC3 and GABARAP families, which mediate selective autophagy, as well as play essential roles in antiviral defense and innate immune signaling [125]. However, it is often observed that viruses subvert autophagy processes to avoid viral protein clearance and repurpose Atg8 proteins as well as autophagosomal membranes for viral replication [125,126]. Considering the perturbances of autophagy in neurodegenerative disease [127,128], the interaction between ERVK IN and Atg8 proteins warrants further investigation.

Consistent with genomic instability profiles in cancer [129], ALS [130], and Alzheimer’s disease [131], the ERVK interactome analysis identified each of these conditions as significant KEGG pathways. Despite differences in clinical presentation, the molecular underpinnings in cancer and neurodegenerative disease are remarkably similar and include alterations in DDR [129,130,132], 14-3-3 expression [133,134], p53 signaling [135,136], p38 signaling [137,138], and Wnt signaling [139,140]—which are all KEGG pathways enriched in the ERVK IN network. AGE-RAGE signaling was also identified as a potential pathway associated with the ERVK IN interactome. Not only is this pathway implicated in diabetic complications [141], but it also plays a role in nuclear response to DNA damage [142], carcinogenesis [143], and inflammatory neurodegenerative diseases [144]. Collectively, our results point to ERVK IN driving a pattern of pathology that, depending on cellular context, may lead to carcinogenesis, neurodegeneration, or contribute to diabetic complications. However, the engagement of DDR can also have beneficial impacts on lifespan extension, depending on tissue context and host genotype; thus, non-pathogenic effects of ERVK IN should also be considered [145,146].

Apart from the importance of putative ERVK IN interaction partners, it is also important to consider which cellular proteins were not associated with the ERVK IN interactome. One interaction that was not predicted was with LEDGF/p75, and indeed, this interactor is limited to partnership with lentiviral integrases [147,148]. Another set of DDR proteins commonly found to impact retroviral integration and replication is the DNA-PK complex [99,149]. HIV integrase directly interacts with Ku70 [120]; while ERVK IN was predicted to be phosphorylated by DNA-PKcs (PRKDC), it contained no ELMs to suggest direct interaction with Ku80 or Ku70. Another apparent difference is the use of EB proteins in microtubule trafficking for HIV and ERVK. ERVK IN contained an SxIP motif that binds EBH domains, whereas HIV capsid conversely has EB-like motifs that interact with SxIP motifs in plus-end tracking protein (+TIP) [150]. These genus-specific distinctions are likely to emerge as important considerations for therapeutic targeting strategies and imply that pharmaceuticals geared toward HIV infection may not consistently translate for use in ERVK-associated disease.

Another consideration that stems from this study is the choice and caveats of using animal models in ERVK research. A diversity of animals outside of the primate lineage are host to ERVK IN-like sequences, such as rodents, ungulates, fish, and insects. Drosophila, a common model organism, also contained ERVK IN-like elements in their genome, specifically LTR retrotransposons flea and Xanthias, as identified by FlyBase (Table A4). The transposable element Xanthias is known to be active in D. melanogaster [151,152], and it shares a degree of similarity with ERVK IN. The presence and activity of these ERVs is an important factor to consider when performing experiments.

It is shocking how little we understand of the impact endogenous viral symbionts have on cellular functioning. Herein, we have predicted that ERVK IN may participate in the modulation of cellular pathways such as DDR, cell cycle regulation, and kinase signaling cascades by way of select protein interaction motifs. The main caveat of in silico predictions is the requirement for experimental validation; while research into ERVK IN is currently underway, this study suggests there remains a myriad of disease-related betaretroviral integrase interactions to explore.

Acknowledgments

The authors would like to thank Samuel Narvey, Megan Rempel and Alex Vandenakker for their peer review of the manuscript drafts.

Author Contributions

Data curation, methodology, validation, investigation, and formal analysis by S.B., I.B. and R.N.D. Conceptualization, supervision, project administration, resources, visualization, and funding acquisition by R.N.D. Writing original draft preparation and review and editing by R.N.D. and I.B. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded in part by the ALS Association (#477) and a Discovery grant from Natural Sciences and Engineering Research Council of Canada (NSERC, RGPIN-2016-05761). S.B. was funded by the University of Winnipeg Wiegand Biology Undergraduate Research Fund.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

National Center for Biotechnology Information (NCBI; https://www.ncbi.nlm.nih.gov/, (accessed on 12 July 2021)) can be used to access sequences listed in the paper.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Dedication

This study is dedicated to patients with ALS—we are working on it!

Appendix A

microorganisms-09-01509-t0A1_Table A1 Table A1 Exogenous viruses with similarity to ERVK integrase based on BLASTp search.

Host	Species	Protein Name	Accession Number	Database	Percent Identity	E Value	Alignment	
Retroviridae—Betaretrovirus	
Mus Musculus	Mouse mammary tumor virus
(MMTV)	MMTV strain BR6 Integrase, partial	5CZ2_A	nr	56.46%	3.00 × 10−71		
Unnamed protein product	CAA25954.1	nr	52.36%	2.00 × 10−70		
Chain A. Integrase
(Core model of the MMTV Intasome)	3JCA_A	nr	51.50%	2.00 × 10−82		
Pr160	NP_056880.1	nr	51.11%	7.00 × 10−76		
Pr160 gag pro pol precursor	AAA46542.1	nr	51.11%	7.00 × 10−76		
p30DU-p13PR-RT-IN	NP_955564.1	nr	51.11%	2.00 × 10−76		
Gag-Pro-Pol polyprotein	P11283.2	nr	51.11%	3.00 × 10−75		
MMTV putative integrase	AAC24859.1	nr	50.37%	5.00 × 10−81		
Gag-Pol-Pro polyprotein, partial	BAA03767.1	nr	49.65%	1.00 × 10−77		
Exogenous MMTV Gag-Pro-Pol	AAF31469.1	nr	49.65%	4.00 × 10−76	•	
Endogenous MTV1 Gag-Pro-Pol	AAF31464.1	nr	49.65%	4.00 × 10−76		
Capra hircus	Enzootic Nasal Tumor Virus
(ENTV)	Pol protein, partial	AVG72436.1	nr	48.79%	3.00 × 10−72		
Pol protein, partial	AVG72437.1	nr	48.79%	3.00 × 10−71		
Pol protein, partial	AVG72438.1	nr	48.79%	7.00 × 10−71		
Pol protein, partial	AVG72441.1	nr	48.39%	3.00 × 10−71		
Pol protein, partial	AVG72440.1	nr	48.39%	4.00 × 10−71		
Pol protein, partial	AVG72435.1	nr	48.39%	2.00 × 10−70		
Gag-Pro-Pol protein	QBP05340.1	nr	47.41%	3.00 × 10−73		
Pol protein, partial	ANG58667.1	nr	47.41%	2.00 × 10−72		
Pol protein	QEQ26602.1	nr	47.41%	3.00 × 10−72		
Pol protein, partial	ANG58699.1	nr	47.41%	2.00 × 10−71	•	
Pol protein, partial	ANG58695.1	nr	47.41%	2.00 × 10−71		
Pol protein, partial	ANG58691.1	nr	47.41%	2.00 × 10−71		
Pol protein, partial	ANG58679.1	nr	47.41%	5.00 × 10−71		
Endogenous ENTV pol protein	QPG92760.1	nr	47.41%	3.00 × 10−73		
Endogenous ENTV pol protein	QPG92768.1	nr	47.41%	1.00 × 10−72		
Gag-Pro-Pol, partial	AOZ60515.1	nr	47.04%	1.00 × 10−72		
Pol protein, partial	ANG58671.1	nr	47.04%	1.00 × 10−71		
Pol protein, partial	ANG58683.1	nr	47.04%	3.00 × 10−70		
Pol protein, partial	ANG58687.1	nr	47.04%	2.00 × 10−71		
Pol protein, partial	ANG58663.1	nr	47.04%	8.00 × 10−71		
Gag-Pro-Pol protein	ANC55859.1	nr	46.67%	5.00 × 10−73		
Gag-Pro-Pol protein, partial	ADI50273.1	nr	46.67%	4.00 × 10−72		
Gag-Pro-Pol protein, partial	AOZ60519.1	nr	46.67%	7.00 × 10−72		
Pol protein, partial	ANG58675.1	nr	46.67%	3.00 × 10−71		
Gag-Pro-Pol fusion, partial	NP_862833.2	nr	46.67%	7.00 × 10−71		
Pol protein, partial	ANG58659.1	nr	46.10%	1.00 × 10−72		
Macaca genus	Mason-Pfizer monkey virus
(M-PMV)	Simian AIDS retrovirus SRV-1-Pol polyprotein	GNLJSA	nr	48.30%	2.00 × 10−70		
Simian retrovirus SRV-5-Pol polyprotein	BBG56792.1	nr	47.57%	5.00 × 10−71	•	
Simian retrovirus SRV-Y-Pol protein, partial	BAM71050.1	nr	47.57%	2.00 × 10−70		
Ovis Aries	Jaagsiekte sheep retrovirus	Reverse transcriptase, partial	CAA77117.1	nr	46.67%	5.00 × 10−75		
Reverse transcriptase, partial	CAA77113.1	nr	46.67%	2.00 × 10−74		
Pol protein	NP_041186.1	nr	46.30%	1.00 × 10−70	•	
BLAST databases: nr denotes non-redundant protein database. Circle symbol: denotes integrase sequences used in protein alignment in Figure 1.

microorganisms-09-01509-t0A2_Table A2 Table A2 Boreoeutherian genomes with similarity to ERVK integrase based on BLASTp searches.

Species	Protein Name	Accession Number	Database	Percent Identity	E Value	
Homo sapiens	Human Endogenous Retrovirus K
(HERV-K/
ERVK)	Pol/env ORF (bases 3878-8257) first start codon at 4172; Xxx; putative	AAA88033.1	nr	100.00%	0	
Endogenous retrovirus group K member 10 Pol protein	P10266.2	nr	100.00%	0	
Gag-Pro-Pol-Env protein	AAD51793.1	nr	100.00%	0	
Pol protein, partial	CAA71417.1	nr	100.00%	2.00 × 10−101	
Endogenous retrovirus group K member 11 Pol protein	Q9UQG0.2	nr	99.64%	0	
Endogenous retrovirus group K member 7 Pol protein	P63135.1	nr	99.29%	0	
Reverse transcriptase, partial	AGQ55918.1	nr	99.28%	1.00 × 10−94	
Reverse transcriptase, partial	AGQ55922.1	nr	99.28%	7.00 × 10−94	
Polymerase, partial	AAO27434.1	nr	99.27%	0	
Gag-Pro-Pol protein	AAD51796.1	nr	99.17%	5.00 × 10−161	
Endogenous retrovirus group K member 113 Pol protein	P63132.1	nr	98.21%	0	
Polymerase, partial	AAK11553.1	nr	98.21%	0	
Endogenous retrovirus group K member 6 Pol protein	Q9BXR3.2	nr	98.21%	0	
Endogenous retrovirus group K member 8 Pol protein	P63133.1	nr	98.21%	0	
Gag-Pro-Pol protein	AAD51797.1	nr	98.21%	0	
Pol protein	CAA76885.1	nr	97.86%	0	
Pol protein	CAA76879.1	nr	97.86%	0	
Polymerase, partial	AAK11554.1	nr	97.86%	0	
Reverse transcriptase, partial	AGQ55928.1	nr	97.84%	6.00 × 10−93	
Reverse transcriptase, partial	AGQ55923.1	nr	97.84%	8.00 × 10−93	
Reverse transcriptase, partial	AGQ55925.1	nr	97.83%	2.00 × 10−92	
Reverse transcriptase, partial	AGQ55927.1	nr	97.83%	3.00 × 10−92	
Reverse transcriptase, partial	AGQ55914.1	nr	97.76%	6.00 × 10−89	
Pol protein	CAA76882.1	nr	97.50%	0	
Endogenous retrovirus group K member 19 Pol protein	Q9WJR5.2	nr	97.50%	0	
Endogenous retrovirus group K member 25 Pol protein	P63136.1	nr	97.50%	0	
Pol protein	AAL60056.1	nr	97.30%	1.00 × 10−152	
Reverse transcriptase, partial	AGQ55924.1	nr	97.12%	2.00 × 10−92	
Reverse transcriptase, partial	AGQ55926.1	nr	97.10%	9.00 × 10−92	
Reverse transcriptase, partial	AGQ55921.1	nr	97.10%	9.00 × 10−92	
Reverse transcriptase, partial	AGQ55919.1	nr	97.10%	1.00 × 10−91	
Pol/env protein, partial	AET81039.1	nr	96.97%	1.00 × 10−81	
Reverse transcriptase, partial	AGQ55920.1	nr	96.38%	2.00 × 10−91	
Pol protein	CAB56603.1	nr	90.13%	2.00 × 10−132	
Endogenous retrovirus group K member 18 Pol protein	Q9QC07.2	nr	90.13%	2.00 × 10−130	
hCG1808534	EAW92672.1	nr	87.38%	3.00 × 10−130	
Macaca
fascicularis	PREDICTED: endogenous retrovirus group K member 8 Pol protein-like	XP_015309771.1	nr	83.77%	2.00 × 10−127	
Chlorocebus
sabaeus	Pol protein, partial	BBC20786.1	nr	47.01%	3.00 × 10−70	
Oryctolagus
cuniculus	PREDICTED: endogenous retrovirus group K member 8 Pol protein-like	XP_017205812.1	nr	49.82%	1.00 × 10−76	
Marmota
marmota	PREDICTED: endogenous retrovirus group K member 11 Pol protein-like	XP_015349278.1	nr	47.96%	4.00 × 10−71	
Ochotona
princeps	Uncharacterized protein LOC105942652	XP_012786727.1	nr	47.33%	1.00 × 10−70	
Mus musculus
(mouse)	Agouti-signaling protein isoform X1	XP_017174599.2	mo	46.93%	6.00 × 10−70	
Contactin-5 isoform X2	XP_036010832.1	mo	44.11%	3.00 × 10−63	
Contactin-5 isoform X1	XP_036010831.1	mo	44.11%	4.00 × 10−63	
Contactin-5 isoform X3	XP_036010833.1	mo	44.11%	4.00 × 10−63	
Protein NYNRIN-like isoform X1	XP_036020530.1	mo	30.15%	9.00 × 10−14	
Uncharacterized protein Gm39701	XP_011237194.2	mo	30.15%	9.00 × 10−14	
Uncharacterized protein LOC118567641, partial	XP_036010828.1	mo	29.71%	2.00 × 10−12	
Fukomys
damarensis	Pol polyprotein	KFO35018.1	nr	45.14%	1.00 × 10−71	
Sus scrofa	TPA: uncharacterized protein	HCZ91355.1	tsa	61.54%	2.00 × 10−65	
TPA: uncharacterized protein	HDB33152.1	tsa	61.54%	2.00 × 10−65	
Endogenous retrovirus group K member 11 Pol protein-like	HDB62800.1	tsa	60.66%	2.00 × 10−17	
TPA: uncharacterized protein	HCZ89879.1	tsa	52.24%	1.00 × 10−39	
Nuclear autoantigenic sperm protein isoform X4	HDA97069.1	tsa	49.06%	2.00 × 10−21	
Nuclear autoantigenic sperm protein isoform 2	HCZ78574.1	tsa	48.86%	5.00 × 10−15	
Nuclear autoantigenic sperm protein isoform 2	HDB80991.1	tsa	48.42%	7.00 × 10−17	
TPA: uncharacterized protein	HCZ87894.1	tsa	42.67%	5.00 × 10−58	
TPA: uncharacterized protein	HDB20633.1	tsa	41.78%	1.00 × 10−53	
TPA: uncharacterized protein	HDC25054.1	tsa	39.81%	7.00 × 10−48	
TPA: uncharacterized protein	HDA81201.1	tsa	38.84%	1.00 × 10−47	
Transmembrane protein 161B isoform X6-like	HDB13612.1	tsa	31.52%	2.00 × 10−13	
TPA: uncharacterized protein	HDC69173.1	tsa	31.07%	2.00 × 10−13	
TPA: uncharacterized protein	HDC69046.1	tsa	30.90%	3.00 × 10−13	
Transmembrane protein 161B isoform X12-like	HDC79805.1	tsa	30.81%	1.00 × 10−12	
Transmembrane protein 161B isoform X12-like	HDB85007.1	tsa	30.81%	1.00 × 10−12	
Transmembrane protein 161B isoform X6-like	HDA96697.1	tsa	30.81%	1.00 × 10−12	
Transmembrane protein 161B isoform X12-like	HDB79678.1	tsa	30.81%	2.00 × 10−12	
Transmembrane protein 161B isoform X6	HDB81123.1	tsa	30.77%	1.00 × 10−11	
Transmembrane protein 161B isoform X6	HDB82421.1	tsa	30.71%	2.00 × 10−10	
TPA: uncharacterized protein	HDC70342.1	tsa	30.41%	6.00 × 10−12	
TPA: uncharacterized protein	HDC70174.1	tsa	30.41%	6.00 × 10−12	
TPA: uncharacterized protein	HDC69016.1	tsa	30.41%	6.00 × 10−12	
putative protein-like	HDB95244.1	tsa	30.23%	3.00 × 10−12	
TPA: uncharacterized protein	HDB49716.1	tsa	30.23%	5.00 × 10−12	
TPA: uncharacterized protein	HDB49718.1	tsa	30.23%	5.00 × 10−12	
TPA: uncharacterized protein	HDC70066.1	tsa	30.23%	5.00 × 10−12	
TPA: uncharacterized protein	HDC69012.1	tsa	30.23%	7.00 × 10−12	
TPA: uncharacterized protein	HDB50090.1	tsa	29.82%	2.00 × 10−11	
TPA: uncharacterized protein	HDB54298.1	tsa	29.65%	1.00 × 10−11	
Transmembrane protein 161B isoform X3-like	HDC79806.1	tsa	29.65%	2.00 × 10−11	
Endogenous retrovirus group K member 25 Pol	HCZ79815.1	tsa	29.65%	3.00 × 10−11	
Transmembrane protein 161B isoform X2-like	HDC79761.1	tsa	29.59%	1.00 × 10−10	
Endogenous retrovirus group K member 25 Pol	HDA78544.1	tsa	29.24%	4.00 × 10−11	
Endogenous retrovirus group K member 25 Pol	HDA79987.1	tsa	29.24%	7.00 × 10−11	
TPA: uncharacterized protein	HDA79350.1	tsa	29.24%	9.00 × 10−11	
Endogenous retrovirus group K member 25 Pol	HDA79988.1	tsa	29.24%	9.00 × 10−11	
TPA: uncharacterized protein	HDA79349.1	tsa	29.24%	1.00 × 10−10	
TPA: uncharacterized protein	HDC13198.1	tsa	29.24%	1.00 × 10−10	
Transmembrane protein 161B isoform X6-like	HDB88647.1	tsa	29.07%	3.00 × 10−11	
TPA: uncharacterized protein	HDA61679.1	tsa	29.07%	5.00 × 10−11	
TPA: uncharacterized protein	HDB82700.1	tsa	29.07%	1.00 × 10−10	
Equus asinus	PREDICTED: endogenous retrovirus group K member 8 Pol protein-like	XP_014715024.1	nr	56.46%	3.00 × 10−95	
Capra hircus	PREDICTED: LOW QUALITY
PROTEIN: endogenous retrovirus group K member 18 Pol protein-like	XP_017905435.1	nr	47.41%	3.00 × 10−71	
Ovis aries	Pol protein	ABV71120.1	nr	47.04%	2.00 × 10−72	
Pol protein	ABV71104.1	nr	46.67%	4.00 × 10−71	
Pol protein	ABV71084.1	nr	46.67%	4.00 × 10−71	
Pol protein	ABV71074.1	nr	46.67%	4.00 × 10−71	
Pol protein	ABV71079.1	nr	46.67%	4.00 × 10−71	
Pol protein	ABV71069.1	nr	46.67%	4.00 × 10−71	
Pol protein (endogenous virus)	AST51848.1	nr	46.67%	5.00 × 10−71	
Pol protein	ABV71094.1	nr	46.30%	2.00 × 10−70	
BLAST databases: nr = non-redundant protein database; mo = model organisms database; tsa = transcriptomics shotgun analysis non-redundant database. TPA = third party annotation.

microorganisms-09-01509-t0A3_Table A3 Table A3 Euteleostomi genomes with similarity to ERVK integrase based on BLASTp searches.

Species	Protein Name	Accession Number	Data base	Percent Identity	E Value	
Micrurus
lemniscatus
carvalhoi	Hypothetical protein, partial	LAA32932.1	tsa	58.47%	2.00 × 10−40	
Hypothetical protein, partial	LAA32929.1	tsa	57.63%	6.00 × 10−40	
Hypothetical protein, partial	LAA32939.1	tsa	48.29%	4.00 × 10−54	
Hypothetical protein, partial	LAA32941.1	tsa	44.00%	1.00 × 10−26	
Zosterops
borbonicus	Hypothetical protein HGM15179_011615	TRZ15504.1	nr	46.97%	3.00 × 10−71	
Zonotrichia
albicollis	Uncharacterized protein LOC106629581	XP_014125095.1	nr	46.24%	1.00 × 10−71	
Micrurus
corallinus	Hypothetical protein, partial	LAA64555.1	tsa	46.21%	2.00 × 10−26	
Hypothetical protein, partial	LAA64556.1	tsa	45.08%	2.00 × 10−21	
Micrurus
lemniscatus lemniscatus	Hypothetical protein, partial	LAA89554.1	tsa	44.57%	4.00 × 10−18	
Hypothetical protein, partial	LAA89545.1	tsa	43.75%	1.00 × 10−23	
Bird
metagenome	Gag-Pro-Pol polyprotein, partial	MBY11728.1	tsa	44.31%	3.00 × 10−43	
Gallirallus
okinawae	Hypothetical protein, partial	LAC45429.1	tsa	43.96%	3.00 × 10−57	
Fundulus
heteroclitus	Integrase core domain, partial	JAQ81073.1	tsa	35.05%	2.00 × 10−11	
Danio rerio
(zebrafish)	Uncharacterized protein LOC108190699	XP_017212567.1	mo	33.64%	4.00 × 10−12	
Uncharacterized protein K02A2.6-like	XP_021334762.1	mo	30.18%	4.00 × 10−11	
Uncharacterized protein K02A2.6-like	XP_017210639.2	mo	29.20%	8.00 × 10−9	
Uncharacterized protein LOC101886116	XP_021327301.1	mo	28.47%	1.00 × 10−5	
Uncharacterized protein LOC110439859	XP_021332670.1	mo	28.17%	0.001	
Uncharacterized protein K02A2.6-like	XP_003199161.1	mo	27.78%	5.00 × 10−10	
Uncharacterized protein K02A2.6-like	XP_002663225.3	mo	27.78%	8.00 × 10−10	
Uncharacterized protein LOC110438047	XP_021323131.1	mo	26.43%	0.006	
Nothobranchius korthausae	Uncharacterized protein	SBQ67355.1	tsa	32.02%	8.00 × 10−11	
Nothobranchius kadleci	Uncharacterized protein	SBP84572.1	tsa	32.00%	8.00 × 10−11	
Nothobranchius furzeri	Uncharacterized protein	SBS54329.1	tsa	31.25%	5.00 × 10−13	
Nothobranchius
rachovii	Uncharacterized protein	SBS11479.1	tsa	30.07%	2.00 × 10−10	
BLAST databases: nr = non-redundant protein database; mo = model organisms database; tsa = transcriptomics shotgun analysis non-redundant database.

microorganisms-09-01509-t0A4_Table A4 Table A4 Nephrozoa (non-boreoeutherian) genomes with similarity to ERVK integrase based on BLASTp searches.

Species	Protein Name	Accession Number	Data base	Percent Identity	E Value	
Onchocerca flexuosa	Integrase core domain protein	OZC05619.1	nr	45.68%	6.00 × 10−73	
Ixodes ricinus	Putative tf2-11 polyprotein	MXV00662.1	tsa	35.81%	2.00 × 10−10	
Putative tick transposon, partial	JAP73380.1	tsa	30.67%	1.00 × 10−11	
Putative tick transposon, partial	JAR90689.1	tsa	30.67%	6.00 × 10−11	
Putative bell all, partial	JAA73039.1	tsa	30.00%	2.00 × 10−10	
Putative gypsy11-i sp, partial	JAP69562.1	tsa	30.00%	2.00 × 10−10	
Putative tick transposon, partial	JAR92200.1	tsa	28.06%	4.00 × 10−13	
Putative transposon tf2-9 polyprotein	MXV00940.1	tsa	27.37%	9.00 × 10−13	
Littorina littorea	Transposon Ty3-G Gag-Pol polyprotein	MBX96210.1	tsa	35.54%	4.00 × 10−12	
Transposon Ty3-I Gag-Pol polyprotein	MBX97975.1	tsa	30.00%	4.00 × 10−14	
Ixodes scapularis	Putative tick transposon, partial	MOY42200.1	tsa	34.29%	4.00 × 10−12	
Putative tick transposon, partial	MOY42203.1	tsa	32.67%	2.00 × 10−13	
Putative tick transposon, partial	MOY42202.1	tsa	32.67%	7.00 × 10−13	
Putative gypsy-17 ga-i, partial	MOY42236.1	tsa	31.09%	2.00 × 10−12	
Hypothetical protein, partial	MOY42219.1	tsa	30.00%	6.00 × 10−11	
Putative gypsy11-i sp, partial	MOY42209.1	tsa	29.17%	7.00 × 10−12	
Putative gypsy21-i sp, partial	MOY42223.1	tsa	29.17%	8.00 × 10−12	
Putative tick transposon, partial	MOY42227.1	tsa	28.50%	4.00 × 10−13	
Putative tick transposon, partial	MOY42214.1	tsa	28.25%	9.00 × 10−11	
Putative gypsy-27 xt-i, partial	MOY35588.1	tsa	26.44%	1.00 × 10−10	
Lygus hesperus	Retrotransposable element Tf2 protein type 3, partial	JAQ12551.1	tsa	33.58%	6.00 × 10−13	
Uncharacterized protein	JAG20083.1	tsa	33.58%	6.00 × 10−13	
Hypothetical protein, partial CM83_13537, partial	JAG31779.1	tsa	29.93%	5.00 × 10−11	
Uncharacterized protein, partial K02A2.6, partial	JAG32119.1	tsa	28.87%	1.00 × 10−11	
Uncharacterized protein, partial K02A2.6, partial	JAG38901.1	tsa	26.82%	8.00 × 10−12	
Amblyomma sculptum	Putative gypsy-7 adi-i, partial	JAU00762.1	tsa	32.88%	1.00 × 10−12	
Putative tick transposon, partial	JAU00733.1	tsa	30.00%	2.00 × 10−10	
Putative tick transposon, partial	JAU00744.1	tsa	30.00%	2.00 × 10−10	
Rhipicephalus
microplus	Putative tick transposon	NIE47479.1	tsa	32.45%	4.00 × 10−11	
Strongylocentrotus purpuratus	Integrase, catalytic core containing protein	MOS08875.1	tsa	32.19%	2.00 × 10−16	
Integrase, catalytic core containing protein	MOS08729.1	tsa	32.03%	7.00 × 10−13	
Integrase, catalytic core containing protein	MOS14051.1	tsa	30.57%	2.00 × 10−13	
Reverse transcriptase domain-containing protein	MOS08491.1	tsa	30.57%	2.00 × 10−13	
Reverse transcriptase domain-containing protein	MOS11069.1	tsa	29.93%	5.00 × 10−12	
Integrase, catalytic core containing protein	MOS08728.1	tsa	29.76%	2.00 × 10−10	
Integrase, catalytic core containing protein	MOS08842.1	tsa	28.57%	4.00 × 10−11	
Integrase, catalytic core containing protein	MOS08745.1	tsa	24.12%	2.00 × 10−10	
Ornithodoros turicata	Putative transposon tf2-9 polyprotein	MBY06492.1	tsa	32.00%	1.00 × 10−10	
Ornithodoros moubata	Esterase D, partial	JAW02195.1	tsa	29.86%	2.00 × 10−10	
Photinus pyralis	Hypothetical protein	JAV53763.1	tsa	29.20%	2.00 × 10−13	
Lepeophtheirus
salmonis	Uncharacterized protein K02A2.6like, partial	CDW28658.1	tsa	28.28%	1.00 × 10−10	
Drosophila
melanogaster
(Fruit fly)	Unnamed protein product	CAA30503.1	nr-DM	28.87%	0.004	
Sd02026p	AAK84933.1	nr-DM	28.57%	3.00 × 10−9	
Blastopia polyprotein	CAA81643.1	nr-DM	28.19%	2.00 × 10−9	
Polyprotein	ACI62137.1	nr-DM	28.00%	2.00 × 10−4	
BLAST databases: nr = non-redundant protein database; nr-DM = non-redundant protein database with Drosophila specified as species search constraint; tsa = transcriptomics shotgun analysis non-redundant database.

microorganisms-09-01509-t0A5_Table A5 Table A5 List of query proteins for STRING analysis based on ELM interaction motifs in ERVK integrase.

Category	ELM	STRING Predicted Interactor
(Gene Name)	Network	
Cleavage	CLV_C14_Caspase3-7	CASP3	•	
CASP7	•	
CLV_PCSK_KEX2_1
CLV_PCSK_PC1ET2_1
CLV_PCSK_SKI1_1	PCSK1	•	
PCSK2	•	
PCSK3	•	
PCSK4	•	
PCSK5	•	
PCSK6	•	
PCSK7	•	
PCSK8	•	
PCSK9	•	
Docking site	DOC_CYCLIN_RXL_1	CCNA1	•	
CCNA2	•	
CCNB1	•	
CCNB2	•	
CCNB3	•	
CCNC	•	
CCND1	•	
CCND2	•	
CCND3	•	
CCNE1	•	
CCNE2	•	
CCNF	•	
CCNG1	•	
CCNG2	•	
CCNH	•	
CCNI	•	
CCNI2	•	
CCNJ	•	
CCNJL	•	
CCNK	•	
CCNL1	•	
CCNL2	•	
CCNO	•	
CCNP	•	
CCNT1	•	
CCNT2	•	
CCNY	•	
CCNYL1	•	
CNTD1	•	
DOC_MAPK_MEF2A_6	MAPK1	•	
MAPK3	•	
MAPK7	•	
MAPK11	•	
MAPK14	•	
DOC_PP1_RVXF_1	PPP1CA	•	
PPP1CB	•	
PPP1CC	•	
PPP3CA	•	
PPP3CB	•	
PPP3CC	•	
DOC_PP2B_LxvP_1	PPP3R1	•	
DOC_USP7_MATH_1
DOC_USP7_UBL2_3	USP7	•	
DOC_WW_Pin1_4	PCIF1	•	
PIN1	•	
SENP6	•	
Ligand	LIG_14-3-3_CanoR_1
LIG_14-3-3_CterR_2	SFN	•	
YWHAB	•	
YWHAE	•	
YWHAG	•	
YWHAH	•	
YWHAQ	•	
YWHAZ	•	
LIG_BIR_II_1	BIRC2	•	
BIRC3	•	
BIRC5	•	
BIRC6	•	
BIRC7	•	
NAIP	•	
XIAP	•	
LIG_BRCT_BRCA1_1	BARD1	•	
BRCA1	•	
CTDP1	•	
DNTT	•	
ECT2	•	
LIG4	•	
MCPH1	•	
MDC1	•	
NBN	•	
PARP1	•	
PARP4	•	
PAXIP1	•	
PES1	•	
RBPJ	•	
REV1	•	
RFC1	•	
TOPBP1	•	
TP53BP1	•	
XRCC1	•	
LIG_FHA_1
LIG_FHA_2	AGGF1	•	
APLF	•	
APTX	•	
CEP170	•	
CEP170B	•	
CHEK2	•	
CHFR	•	
FHAD1	•	
FOXK1	•	
FOXK2	•	
KIF13A	•	
KIF13B		
KIF14	•	
KIF16B		
KIF1A	•	
KIF1B	•	
KIF1C		
MCRS1	•	
MDC1	•	
MKI67	•	
MLLT4	•	
NBN	•	
PHF12	•	
PPP1R8	•	
RNF8	•	
SLC4A1AP	•	
SLMAP	•	
SNIP1	•	
STARD9	•	
TCF19	•	
TIFA	•	
TIFAB	•	
LIG_CSL_BTD_1	CHEK2	•	
MRC1	•	
RAD9A	•	
XRCC1	•	
XRCC4	•	
LIG_LIR_Gen_1
LIG_LIR_Nem_4	GABARAP		
GABARAPL1		
GABARAPL2	•	
MAP1LC3A		
MAP1LC3B		
MAP1LC3B2	•	
MAP1LC3C		
LIG_Pex14_1	PEX13	•	
PEX14	•	
LIG_SH2_PTP2	PLCG1	•	
PTPN11	•	
LIG_SH2_SRC	BLK	•	
FGR	•	
FRK	•	
FYN	•	
HCK	•	
LCK	•	
LYN	•	
SRC	•	
YES1	•	
LIG_SH2_STAP1	STAP1	•	
LIG_TYR_ITIM	ABL1	•	
ABL2	•	
FYN	•	
LCK	•	
MATK	•	
PI3KCA	•	
PLCG1	•	
SH2D1A	•	
SHF	•	
PTPN6	•	
PTPN11	•	
SRC	•	
SYK	•	
LIG_SH2_STAT3	STAT3	•	
LIG_SH2_STAT5	STAT5A	•	
STAT5B	•	
LIG_SH3_3	ARHGEF7	•	
CTTN	•	
LIG_SxIP_EBH_1	MAPRE1	•	
MAPRE2	•	
MAPRE3	•	
LIG_TRAF2_1	TRAF2	•	
LIG_WD40_WDR5_VDV_2	WDR5	•	
Modification	MOD_CK1_1	CSNK1A1	•	
MOD_CK2_1	CSNK2A1	•	
MOD_GSK3_1	GSK3A	•	
GSK3B	•	
MOD_N-GLC_1	DDOST	•	
MOD_NEK2_1	NEK2	•	
MOD_PIKK_1	ATM	•	
ATR	•	
mTOR	•	
PRKDC	•	
SMG1	•	
TRRAP	•	
MOD_PKA_2	PAK1	•	
PRKACA	•	
PRKACB	•	
PRKACG	•	
PRKCA	•	
PRKCB	•	
PRKCE	•	
PRKCG	•	
PRKCH	•	
PRKCI	•	
PRKCQ	•	
PRKCZ	•	
MOD_Plk_1
MOD_Plk_4	PLK1	•	
PLK2	•	
PLK3	•	
PLK4	•	
MOD_ProDKin_1	MAPK11	•	
MAPK12		
MAPK13		
MAPK14	•	
MOD_SUMO_rev_2	SUMO2	•	
Targeting	TRG_ENDOCYTIC_2	AP1M1	•	
AP2M1	•	
AP3M1	•	
AP3M2		
AP4M1	•	
AP5M1		
ARCN1		
FCHO1	•	
FCHO2	•	
SGIP1	•	
STON1	•	
STON2	•	
TRG_Pf-PMV_PEXEL_1	None	
Circle symbol: denotes protein depicted in network analysis in Figure 3.

microorganisms-09-01509-t0A6_Table A6 Table A6 Full list of KEGG pathways identified in the STRING analysis of the ERVK integrase interactome.

KEGG Term ID	Term Description	Observed Gene Count	Background Gene Count	Strength	False Discovery Rate	
hsa04218	Cellular senescence	28	156	1.27	2.30 × 10−23	
hsa05203	Viral carcinogenesis	29	183	1.21	3.47 × 10−23	
hsa04110	Cell cycle	25	123	1.32	2.38 × 10−22	
hsa04114	Oocyte meiosis	23	116	1.31	2.13 × 10−20	
hsa05169	Epstein–Barr virus infection	24	194	1.11	4.01 × 10−17	
hsa05205	Proteoglycans in cancer	23	195	1.08	4.79 × 10−16	
hsa04650	Natural killer cell-mediated cytotoxicity	19	124	1.2	3.96 × 10−15	
hsa04068	FoxO signaling pathway	19	130	1.18	7.58 × 10−15	
hsa04750	Inflammatory mediator regulation of TRP channels	17	92	1.28	8.12 × 10−15	
hsa05167	Kaposi’s sarcoma-associated herpesvirus infection	21	183	1.07	1.30 × 10−14	
hsa04720	Long-term potentiation	15	64	1.38	1.77 × 10−14	
hsa05161	Hepatitis B	19	142	1.14	2.19 × 10−14	
hsa05206	MicroRNAs in cancer	19	149	1.12	4.49 × 10−14	
hsa04370	VEGF signaling pathway	14	59	1.39	1.11 × 10−13	
hsa04660	T cell receptor signaling pathway	16	99	1.22	2.39 × 10−13	
hsa04012	ErbB signaling pathway	15	83	1.27	3.37 × 10−13	
hsa04611	Platelet activation	17	123	1.15	3.37 × 10−13	
hsa04921	Oxytocin signaling pathway	18	149	1.09	4.19 × 10−13	
hsa04115	p53 signaling pathway	14	68	1.33	4.53 × 10−13	
hsa05200	Pathways in cancer	29	515	0.76	6.20 × 10−13	
hsa05166	HTLV-I infection	21	250	0.94	1.82 × 10−12	
hsa04933	AGE-RAGE signaling pathway in diabetic complications	15	98	1.2	2.24 × 10−12	
hsa04510	Focal adhesion	19	197	1	2.57 × 10−12	
hsa04659	Th17 cell differentiation	15	102	1.18	3.46 × 10−12	
hsa05031	Amphetamine addiction	13	65	1.31	3.95 × 10−12	
hsa04728	Dopaminergic synapse	16	128	1.11	4.97 × 10−12	
hsa04658	Th1 and Th2 cell differentiation	14	88	1.21	7.29 × 10−12	
hsa05165	Human papillomavirus infection	22	317	0.85	1.27 × 10−11	
hsa04914	Progesterone-mediated oocyte maturation	14	94	1.19	1.52 × 10−11	
hsa04310	Wnt signaling pathway	16	143	1.06	2.02 × 10−11	
hsa04390	Hippo signaling pathway	16	152	1.04	4.56 × 10−11	
hsa04062	Chemokine signaling pathway	17	181	0.99	5.10 × 10−11	
hsa04917	Prolactin signaling pathway	12	69	1.25	1.03 × 10−10	
hsa04662	B cell receptor signaling pathway	12	71	1.24	1.35 × 10−10	
hsa04919	Thyroid hormone signaling pathway	14	115	1.1	1.47 × 10−10	
hsa04064	NF-kappa B signaling pathway	13	93	1.16	1.57 × 10−10	
hsa04270	Vascular smooth muscle contraction	14	119	1.08	2.11 × 10−10	
hsa04360	Axon guidance	16	173	0.98	2.24 × 10−10	
hsa05162	Measles	14	133	1.04	7.76 × 10−10	
hsa05223	Non-small cell lung cancer	11	66	1.23	9.08 × 10−10	
hsa04666	Fc gamma R-mediated phagocytosis	12	89	1.14	1.18 × 10−9	
hsa04380	Osteoclast differentiation	13	124	1.03	3.48 × 10−9	
hsa01521	EGFR tyrosine kinase inhibitor resistance	11	78	1.16	4.18 × 10−9	
hsa04010	MAPK signaling pathway	18	293	0.8	5.87 × 10−9	
hsa04931	Insulin resistance	12	107	1.06	7.37 × 10−9	
hsa04910	Insulin signaling pathway	13	134	1	7.61 × 10−9	
hsa04724	Glutamatergic synapse	12	112	1.04	1.14 × 10−8	
hsa04151	PI3K-Akt signaling pathway	19	348	0.75	1.17 × 10−8	
hsa04912	GnRH signaling pathway	11	88	1.11	1.17 × 10−8	
hsa04664	Fc epsilon RI signaling pathway	10	67	1.19	1.30 × 10−8	
hsa04071	Sphingolipid signaling pathway	12	116	1.03	1.51 × 10−8	
hsa04722	Neurotrophin signaling pathway	12	116	1.03	1.51 × 10−8	
hsa01522	Endocrine resistance	11	95	1.08	2.24 × 10−8	
hsa04014	Ras signaling pathway	15	228	0.83	5.08 × 10−8	
hsa04210	Apoptosis	12	135	0.96	6.74 × 10−8	
hsa05152	Tuberculosis	13	172	0.89	1.01 × 10−7	
hsa04540	Gap junction	10	87	1.07	1.11 × 10−7	
hsa05221	Acute myeloid leukemia	9	66	1.15	1.42 × 10−7	
hsa05214	Glioma	9	68	1.13	1.74 × 10−7	
hsa05222	Small cell lung cancer	10	92	1.05	1.74 × 10−7	
hsa01524	Platinum drug resistance	9	70	1.12	2.13 × 10−7	
hsa04215	Apoptosis—multiple species	7	31	1.37	2.13 × 10−7	
hsa04926	Relaxin signaling pathway	11	130	0.94	3.72 × 10−7	
hsa04015	Rap1 signaling pathway	13	203	0.82	5.46 × 10−7	
hsa04960	Aldosterone-regulated sodium reabsorption	7	37	1.29	5.77 × 10−7	
hsa04668	TNF signaling pathway	10	108	0.98	6.23 × 10−7	
hsa04261	Adrenergic signaling in cardiomyocytes	11	139	0.91	6.58 × 10−7	
hsa05145	Toxoplasmosis	10	109	0.98	6.58 × 10−7	
hsa04725	Cholinergic synapse	10	111	0.97	7.54 × 10−7	
hsa05120	Epithelial cell signaling in Helicobacter pylori infection	8	66	1.1	1.53 × 10−6	
hsa04340	Hedgehog signaling pathway	7	46	1.2	1.97 × 10−6	
hsa04961	Endocrine and other factor-regulated calcium reabsorption	7	47	1.19	2.22 × 10−6	
hsa04066	HIF-1 signaling pathway	9	98	0.98	2.44 × 10−6	
hsa04520	Adherens junction	8	71	1.06	2.44 × 10−6	
hsa04916	Melanogenesis	9	98	0.98	2.44 × 10−6	
hsa05225	Hepatocellular carcinoma	11	163	0.84	2.56 × 10−6	
hsa04621	NOD-like receptor signaling pathway	11	166	0.83	2.99 × 10−6	
hsa05014	Amyotrophic lateral sclerosis (ALS)	7	50	1.16	2.99 × 10−6	
hsa05220	Chronic myeloid leukemia	8	76	1.04	3.62 × 10−6	
hsa05020	Prion diseases	6	33	1.27	4.44 × 10−6	
hsa04020	Calcium signaling pathway	11	179	0.8	5.69 × 10−6	
hsa04670	Leukocyte transendothelial migration	9	112	0.92	6.16 × 10−6	
hsa04726	Serotonergic synapse	9	112	0.92	6.16 × 10−6	
hsa04723	Retrograde endocannabinoid signaling	10	148	0.84	7.20 × 10−6	
hsa04727	GABAergic synapse	8	88	0.97	9.28 × 10−6	
hsa04934	Cushing’s syndrome	10	153	0.83	9.30 × 10−6	
hsa04924	Renin secretion	7	63	1.06	1.09 × 10−5	
hsa04024	cAMP signaling pathway	11	195	0.76	1.14 × 10−5	
hsa04657	IL-17 signaling pathway	8	92	0.95	1.20 × 10−5	
hsa04022	cGMP-PKG signaling pathway	10	160	0.81	1.28 × 10−5	
hsa04140	Autophagy—animal	9	125	0.87	1.28 × 10−5	
hsa04630	Jak-STAT signaling pathway	10	160	0.81	1.28 × 10−5	
hsa04713	Circadian entrainment	8	93	0.95	1.28 × 10−5	
hsa05146	Amoebiasis	8	94	0.94	1.32 × 10−5	
hsa05215	Prostate cancer	8	97	0.93	1.62 × 10−5	
hsa05231	Choline metabolism in cancer	8	98	0.92	1.72 × 10−5	
hsa04371	Apelin signaling pathway	9	133	0.84	1.94 × 10−5	
hsa04930	Type II diabetes mellitus	6	46	1.13	2.04 × 10−5	
hsa03450	Non-homologous end-joining	4	13	1.5	3.50 × 10−5	
hsa04072	Phospholipase D signaling pathway	9	145	0.81	3.61 × 10−5	
hsa05226	Gastric cancer	9	147	0.8	3.96 × 10−5	
hsa05210	Colorectal cancer	7	85	0.93	5.70 × 10−5	
hsa04217	Necroptosis	9	155	0.78	5.77 × 10−5	
hsa04730	Long-term depression	6	60	1.01	7.67 × 10−5	
hsa04925	Aldosterone synthesis and secretion	7	93	0.89	9.48 × 10−5	
hsa04530	Tight junction	9	167	0.74	9.70 × 10−5	
hsa05131	Shigellosis	6	63	0.99	9.70 × 10−5	
hsa05010	Alzheimer’s disease	9	168	0.74	9.98 × 10−5	
hsa05164	Influenza A	9	168	0.74	9.98 × 10−5	
hsa05160	Hepatitis C	8	131	0.8	0.00011	
hsa03440	Homologous recombination	5	40	1.11	0.00012	
hsa04922	Glucagon signaling pathway	7	100	0.86	0.00014	
hsa05140	Leishmaniasis	6	70	0.95	0.00016	
hsa05168	Herpes simplex infection	9	181	0.71	0.00016	
hsa04971	Gastric acid secretion	6	72	0.93	0.00018	
hsa04918	Thyroid hormone synthesis	6	73	0.93	0.00019	
hsa05133	Pertussis	6	74	0.92	0.0002	
hsa05212	Pancreatic cancer	6	74	0.92	0.0002	
hsa05224	Breast cancer	8	147	0.75	0.00021	
hsa04150	mTOR signaling pathway	8	148	0.75	0.00022	
hsa05110	Vibrio cholerae infection	5	48	1.03	0.00025	
hsa04810	Regulation of actin cytoskeleton	9	205	0.66	0.00037	
hsa04911	Insulin secretion	6	84	0.87	0.00037	
hsa05130	Pathogenic Escherichia coli infection	5	53	0.99	0.00037	
hsa04970	Salivary secretion	6	86	0.86	0.00041	
hsa05416	Viral myocarditis	5	56	0.96	0.00046	
hsa05032	Morphine addiction	6	91	0.83	0.00053	
hsa05213	Endometrial cancer	5	58	0.95	0.00053	
hsa04915	Estrogen signaling pathway	7	133	0.73	0.00063	
hsa05418	Fluid shear stress and atherosclerosis	7	133	0.73	0.00063	
hsa04213	Longevity regulating pathway—multiple species	5	61	0.93	0.00064	
hsa04550	Signaling pathways regulating pluripotency of stem cells	7	138	0.72	0.00076	
hsa05211	Renal cell carcinoma	5	68	0.88	0.001	
hsa04920	Adipocytokine signaling pathway	5	69	0.87	0.0011	
hsa05219	Bladder cancer	4	41	1	0.0013	
hsa04211	Longevity regulating pathway	5	88	0.77	0.0029	
hsa04923	Regulation of lipolysis in adipocytes	4	53	0.89	0.0031	
hsa04120	Ubiquitin mediated proteolysis	6	134	0.66	0.0033	
hsa04070	Phosphatidylinositol signaling system	5	97	0.72	0.0043	
hsa05034	Alcoholism	6	142	0.64	0.0043	
hsa05142	Chagas disease (American trypanosomiasis)	5	101	0.71	0.005	
hsa04620	Toll-like receptor signaling pathway	5	102	0.7	0.0051	
hsa04932	Non-alcoholic fatty liver disease (NAFLD)	6	149	0.62	0.0053	
hsa05230	Central carbon metabolism in cancer	4	65	0.8	0.0059	
hsa03410	Base excision repair	3	33	0.97	0.0066	
hsa05143	African trypanosomiasis	3	34	0.96	0.0071	
hsa04622	RIG-I-like receptor signaling pathway	4	70	0.77	0.0075	
hsa05218	Melanoma	4	72	0.76	0.0081	
hsa05216	Thyroid cancer	3	37	0.92	0.0087	
hsa05202	Transcriptional misregulation in cancer	6	169	0.56	0.0091	
hsa04152	AMPK signaling pathway	5	120	0.63	0.0093	
hsa04962	Vasopressin-regulated water reabsorption	3	44	0.85	0.0132	
hsa05132	Salmonella infection	4	84	0.69	0.0132	
hsa03015	mRNA surveillance pathway	4	89	0.67	0.0157	
hsa04913	Ovarian steroidogenesis	3	49	0.8	0.0171	
hsa05030	Cocaine addiction	3	49	0.8	0.0171	
hsa03460	Fanconi anemia pathway	3	51	0.78	0.0187	
hsa05134	Legionellosis	3	54	0.76	0.0215	
hsa04137	Mitophagy—animal	3	63	0.69	0.0314	
hsa04714	Thermogenesis	6	228	0.43	0.0314	
hsa04927	Cortisol synthesis and secretion	3	63	0.69	0.0314	
hsa04976	Bile secretion	3	71	0.64	0.0413	
hsa04136	Autophagy—other	2	30	0.84	0.045	

Figure 1 ERVK integrase and exogenous betaretrovirus integrases share common eukaryotic linear motifs. In silico examination of the conserved and differential eukaryotic linear motifs (ELMs) within Endogenous retrovirus-K (ERVK) and similar betaretroviral integrases. A betaretroviral integrase consensus sequence was constructed using GenBank sequences as follows: Endogenous retrovirus-K (ERVK; P10266.2), Exogenous mouse mammary tumor virus (MMTV; AAF31469.1), Mason–Pfizer monkey virus 5 (M-PMV; BBG56792.1), Enzootic nasal tumor virus (ENTV; ANG58699.1) and Jaagsiekte sheep retrovirus (JSRV; NP_041186.1). The HHCC region and DDE active site motif (gray, with key aa. in black) was positioned based on Conserved Domains annotations. ELMs were grouped based on related pathways: DNA damage response (dark blue), cell cycle (cyan), cell signaling (green), cell trafficking (magenta), autophagy (mauve), and glycosylation (red). ELM abbreviations used include: 14-3-3 = 14-3-3 protein interaction site, BRCT = BRCA1 C-terminus domain interaction site, CK1-P = casein kinase 1 phosphorylation site, Cyclin = cyclin docking site, EBH = end binding homology domain interaction site, ERK/p38 = ERK1/2 and p38 MAP kinase docking site, FHA = Forkhead-associated domain interaction site, GlyNH = glycosaminoglycan attachment site, GSK3-P = GSK3 phosphorylation site, IAP = inhibitor of apoptosis protein interaction site, ITIM = immunoreceptor tyrosine-based inhibitory motif, LIR = site that interacts with Atg8 protein family members, NEK2-P = NEK2 phosphorylation site, p38-P = p38 phosphorylation site, Pex14 = peroxisomal membrane docking via Pex14, PIKK-P = PIKK family phosphorylation site, Pin1 = docking site for Pin1 via WW domain interaction, PKA-P = PKA phosphorylation site, PLK-P = polo-like kinase phosphorylation site, PP1c = protein phosphatase 1 catalytic subunit docking motif, SH2 = Src homology 2 domain interaction motif, SH3 = interaction site for non-canonical class I recognition specificity SH3 domains, STAT3 = STAT3 SH2 domain binding motif, STAT5 = STAT5 SH2 domain binding motif, TRAF2 = major TRAF2 binding consensus motif, USP7 = USP7 MATH (M) or UBL2 (U) domain interaction sites, WDR5 = interaction motif for WDR5 via WW domain interaction. Asterisks indicate ELMs unique to ERVK. Sequence alignment and annotation were performed using Geneious Prime software.

Figure 2 ERVK integrase and similar endogenous integrases share eukaryotic linear motifs patterns. Modified OneZoom image illustrating the conservation of ELM motifs in integrases from eukaryotic organisms (Homo sapiens, Macaca fasicicularis, Fukomys damarensis, Ochotona princeps, Equis asinus, and Capra hircus). Motifs are color-grouped according to function; DDR (blue), cell cycle (cyan), cell signaling (green), and intracellular trafficking (magenta). The number in each colored shape refers to the number of motifs with the respective integrase enzyme.

Figure 3 Predicted ERVK integrase interactome. Cellular proteins containing complementary interaction motifs for ELMs identified in Endogenous retrovirus-K (ERVK) integrase were listed as query proteins for STRING network analysis. Only query proteins with a minimum interaction score of 0.9 based on experiments and databases as interaction sources are indicated. Edges indicate both functional and physical protein associations. A payload list was generated to color nodes and hubs related to dominant pathways: DNA damage response (dark blue), cell cycle (cyan), apoptosis (black), cell signaling (green), and cell transport (magenta).

Figure 4 KEGG pathways associated with ERVK integrase interactome. Predicted interacting partners were curated based on ERVK IN ELM motifs and submitted to STRING network analysis software. Enriched KEGG pathways are reported along with significance scores (−log10 p value). ERVK IN is predicted to interact with cellular pathways involved in the cell cycle, cell signaling, immunity, and inflammation, as well as disease pathways associated with several cancers, the nervous system, and diabetes.

microorganisms-09-01509-t001_Table 1 Table 1 ELM motifs in integrases from ERVK and exogenous betaretroviruses.

ELM Motif	ELM Accession	Alignment Notation	Integrase	Conservation	
ERVK	MMTV	M-PMV	ENTV	JSRV	
Cleavage and
degradation	CLV_C14_Caspase3-7	ELME000321		1	0	0	0	2	0.4	
CLV_PCSK_KEX2_1	ELME000108		1	0	0	0	0	0.2	
CLV_NRD_NRD_1	ELME000102		0	1	0	1	1	0.6	
CLV_PCSK_PC1ET2_1	ELME000100		1	0	0	0	0	0.2	
CLV_PCSK_SKI1_1	ELME000146		5	4	4	1	0	0.8	
DEG_APCC_DBOX_1	ELME000231		0	0	0	1	0	0.2	
Docking	DOC_CKS1_1	ELME000358		0	1	0	0	0	0.2	
DOC_CYCLIN_RxL_1	ELME000106	Cyclin	2	0	2	0	0	0.4	
DOC_MAPK_gen_1	ELME000233		0	2	0	1	1	0.6	
DOC_MAPK_MEF2A_6	ELME000432	ERK/p38	1	1	0	1	1	0.8	
DOC_PP1_RVXF_1	ELME000137	PP1c	3	1	1	1	1	1.0	
DOC_PP2B_LxvP_1	ELME000367		1	0	1	0	0	0.4	
DOC_PP4_FxxP_1	ELME000477		0	1	0	1	1	0.6	
DOC_USP7_MATH_1	ELME000239	USP7_M	1	3	0	2	2	0.8	
DOC_USP7_UBL2_3	ELME000394	USP7_U	1	0	1	0	0	0.4	
DOC_WW_Pin1_4	ELME000136	Pin1	3	6	1	3	2	1.0	
Ligand	LIG_14-3-3_CanoR_1	ELME000417	14-3-3	2	1	1	2	2	1.0	
LIG_14-3-3_CterR_2	ELME000418	14-3-3 *	1	0	0	0	0	0.2	
LIG_Actin_WH2_2	ELME000313		0	1	0	1	1	0.6	
LIG_APCC_ABBA_1	ELME000435		0	1	0	0	0	0.2	
LIG_BIR_II_1	ELME000285	IAP	1	1	1	1	1	1.0	
LIG_BIR_III_4	ELME000293		0	0	0	1	0	0.2	
LIG_BRCT_BRCA1_1	ELME000197	BRCT	1	0	1	1	1	0.8	
LIG_BRCT_BRCA1_2	ELME000198	BRCT1 *	1	0	0	0	0	0.2	
LIG_CSL_BTD_1	ELME000410		1	1	0	0	0	0.4	
LIG_EH1_1	ELME000148		0	0	1	0	1	0.4	
LIG_eIF4E_1	ELME000317		0	1	0	0	0	0.2	
LIG_FHA_1	ELME000052	FHA	5	1	2	0	1	0.8	
LIG_FHA_2	ELME000220	FHA 2	1	1	1	0	0	0.6	
LIG_LIR_Apic_2	ELME000369		0	3	2	1	1	0.8	
LIG_LIR_Gen_1	ELME000368	LIR	2	0	0	0	0	0.2	
LIG_MAD2	ELME000167		0	0	0	1	0	0.2	
LIG_NRBOX	ELME000045		0	0	0	1	0	0.2	
LIG_LIR_Nem_3	ELME000370		0	6	7	1	4	0.8	
LIG_Pex14_1	ELME000080	Pex14	1	0	0	0	0	0.2	
LIG_Pex14_2	ELME000328	Pex14	2	2	1	1	1	1.0	
LIG_PTB_Apo_2	ELME000122		0	0	1	0	1	0.4	
LIG_PTB_Phospho_1	ELME000095		0	0	0	0	1	0.2	
LIG_RPA_C_Fungi	ELME000382		0	0	1	1	1	0.6	
LIG_SH2_CRK	ELME000458		0	2	0	0	0	0.2	
LIG_SH2_NCK_1	ELME000474		0	1	0	0	0	0.2	
LIG_SH2_PTP2	ELME000083	SH2	1	1	0	1	1	0.8	
LIG_SH2_SRC	ELME000081	SH2	1	1	1	1	1	1.0	
LIG_SH2_STAP1	ELME000465		2	1	0	0	0	0.4	
LIG_SH2_STAT3	ELME000163	STAT3	2	1	1	1	1	1.0	
LIG_SH2_STAT5	ELME000182	STAT5	3	3	2	3	3	1.0	
LIG_SH3_1	ELME000005		0	1	0	0	0	0.2	
LIG_SH3_3	ELME000155	SH3	1	2	1	1	1	1.0	
LIG_SH3_4	ELME000156		0	0	0	1	0	0.2	
LIG_SxIP_EBH_1	ELME000254	EBH	1	1	1	1	2	1.0	
LIG_TRAF2_1	ELME000117	TRAF2	1	1	0	1	1	0.8	
LIG_TYR_ITIM	ELME000020	ITIM	1	1	1	1	1	1.0	
LIG_Vh1_VBS_1	ELME000438		0	0	0	0	1	0.2	
LIG_WD40_WDR5_VDV_2	ELME000365	WDR5	2	10	3	8	9	1.0	
LIG_WW_3	ELME000135		0	1	0	0	0	0.2	
Modification	MOD_CDK_SPK_2	ELME000429		0	0	1	0	0	0.2	
MOD_CDK_SPxK_1	ELME000153		0	1	0	0	0	0.2	
MOD_CK1_1	ELME000063	CK1-P	1	3	2	4	4	1.0	
MOD_CK2_1	ELME000064		3	3	1	0	0	0.6	
MOD_Cter_Amidation	ELME000093		1	0	0	0	0	0.2	
MOD_GlcNHglycan	ELME000085	GlyNH	1	2	3	1	2	1.0	
MOD_GSK3_1	ELME000053	GSK3-P	3	4	2	1	2	1.0	
MOD_NEK2_1	ELME000336	NEK2-P	2	3	3	2	4	1.0	
MOD_NEK2_2	ELME000337		0	0	1	0	0	0.2	
MOD_N-GLC_1	ELME000070		1	0	1	2	0	0.6	
MOD_PIKK_1	ELME000202		5	0	1	0	0	0.4	
MOD_PKA_1	ELME000008		0	1	0	0	0	0.2	
MOD_PKA_2	ELME000062	PKA-P	1	0	1	2	2	0.8	
MOD_Plk_1	ELME000442	PLK-P	4	1	2	1	1	1.0	
MOD_Plk_4	ELME000444		1	0	1	0	0	0.4	
MOD_ProDKin_1	ELME000159	p38-P	3	6	1	3	2	1.0	
MOD_SUMO_rev_2	ELME000393		1	1	0	0	0	0.4	
Target	TRG_ENDOCYTIC_2	ELME000120		2	4	2	1	1	1.0	
TRG_Pf-PMV_PEXEL_1	ELME000462		1	2	1	1	1	1.0	
GenBank accession numbers for betaretroviral integrase sequences are as follows: Endogenous retrovirus-K (ERVK; P10266.2), Exogenous mouse mammary tumor virus (MMTV; AAF31469.1), Mason–Pzifer monkey virus 5 (M-PMV; BBG56792.1), Enzootic nasal tumor virus (ENTV; ANG58699.1) and Jaagsiekte sheep retrovirus (JSRV; NP_041186.1). Asterisk indicates ERVK-specific ELM motif in Figure 1.

microorganisms-09-01509-t002_Table 2 Table 2 ELM motifs in ERVK integrase and similar endogenous integrases in eukaryotes.

ELM Motif	ELM Accession	ERVK Integrase
(Homo sapiens)	ERVK-8 Pol protein-Like
(Macaca fascicularis)	Pol Protein
(Chlorocebus sabaeus)	Pol Protein
(Fukomys darmarensis)	Putative Protein
(Ochonta princeps)	ERVK-8 pol Protein-Like
(Equus asinus)	ERVK-18 pol Protein-Like
(Capra hircus)	Pol Protein
(Ovis aries)	Putative Protein
(Zonotrichia albicollis)	Putative Protein
(Zosterops borbonicus)	Integrase
(Onchocerca flexuosa)	Motif conservation	
Cleavage	CLV_C14_Caspase3-7	ELME000321	1	0	0	0	1	0	0	0	0	0	0	0.2	
CLV_NRD_NRD_1	ELME000102	0	0	0	0	0	0	0	1	0	0	1	0.2	
CLV_PCSK_KEX2_1	ELME000108	1	2	0	0	0	0	0	0	0	1	0	0.3	
CLV_PCSK_PC1ET2_1	ELME000100	1	2	0	0	0	0	0	0	0	1	0	0.3	
CLV_PCSK_SKI1_1	ELME000146	5	3	4	3	7	8	0	0	3	5	2	0.8	
Degradation	DEG_APCC_DBOX_1	ELME000231	0	0	0	0	0	0	0	0	0	0	1	0.1	
DEG_MDM2_SWIB_1	ELME000184	0	0	0	0	0	0	0	0	1	0	0	0.1	
Docking	DOC_CKS1_1	ELME000358	0	1	0	0	2	0	0	0	1	2	1	0.5	
DOC_CYCLIN_RxL_1	ELME000106	2	1	2	0	2	2	0	0	3	3	1	0.7	
DOC_MAPK_DCC_7	ELME000433	0	0	0	1	0	0	0	0	0	0	1	0.2	
DOC_MAPK_gen_1	ELME000233	0	1	0	3	5	2	1	1	2	4	1	0.8	
DOC_MAPK_HePTP_8	ELME000434	0	0	0	0	0	0	0	0	0	0	1	0.1	
DOC_MAPK_MEF2A_6	ELME000432	1	1	0	0	2	1	1	1	3	4	3	0.8	
DOC_PP1_RVXF_1	ELME000137	3	3	1	1	0	0	1	1	0	1	1	0.7	
DOC_PP2A_B56_1	ELME000425	0	0	0	1	0	0	0	0	0	0	0	0.1	
DOC_PP2B_LxvP_1	ELME000367	1	1	2	0	0	0	0	0	1	1	1	0.5	
DOC_PP2B_PxIxI_1	ELME000237	0	0	0	0	1	0	0	0	0	0	0	0.1	
DOC_PP4_FxxP_1	ELME000477	0	1	1	1	1	1	1	0	0	0	2	0.6	
DOC_USP7_MATH_1	ELME000239	1	3	0	1	1	1	2	2	3	1	3	0.9	
DOC_USP7_MATH_2	ELME000240	0	1	0	0	1	0	0	0	0	0	0	0.2	
DOC_USP7_UBL2_3	ELME000394	1	2	0	0	0	0	0	0	1	3	0	0.4	
DOC_WW_Pin1_4	ELME000136	3	0	1	0	6	2	2	2	3	3	1	0.8	
Ligand	LIG_14-3-3_CanoR_1	ELME000417	2	4	1	1	2	2	1	2	3	1	1	1.0	
LIG_14-3-3_CterR_2	ELME000418	1	0	0	0	0	0	0	0	0	0	0	0.1	
LIG_Actin_WH2_2	ELME000313	0	0	1	1	0	0	1	1	0	1	1	0.5	
LIG_APCC_ABBA_1	ELME000435	0	0	0	1	0	1	0	0	0	0	0	0.2	
LIG_BIR_II_1	ELME000285	1	1	1	1	1	1	1	1	1	1	1	1.0	
LIG_BIR_III_4	ELME000293	0	0	0	0	0	0	1	1	0	0	0	0.2	
LIG_BRCT_BRCA1_1	ELME000197	1	2	0	1	0	0	1	1	0	0	2	0.5	
LIG_BRCT_BRCA1_2	ELME000198	1	1	0	0	0	0	0	0	0	0	0	0.2	
LIG_CSL_BTD_1	ELME000410	1	0	1	1	1	1	0	0	0	0	0	0.5	
LIG_deltaCOP1_diTrp_1	ELME000459	0	0	0	0	0	0	0	0	1	0	0	0.1	
LIG_EH1_1	ELME000148	0	0	1	0	0	0	1	1	0	0	0	0.3	
LIG_eIF4E_1	ELME000317	0	0	0	0	1	0	0	0	0	0	1	0.2	
LIG_FHA_1	ELME000052	5	5	5	3	2	0	0	1	1	1	4	0.8	
LIG_FHA_2	ELME000220	1	1	0	1	3	2	0	0	0	1	0	0.5	
LIG_LIR_Apic_2	ELME000369	0	3	3	2	1	2	1	1	1	0	1	0.8	
LIG_LIR_Gen_1	ELME000368	2	1	1	1	2	1	0	1	1	1	0	0.8	
LIG_LIR_Nem_3	ELME000370	6	5	7	6	7	3	4	4	1	3	6	1.0	
LIG_LYPXL_S_1	ELME000294	0	0	0	0	0	0	0	0	0	0	1	0.1	
LIG_PCNA_PIPBox_1	ELME000140	0	0	1	0	0	0	0	0	0	0	0	0.1	
LIG_PCNA_yPIPBox_3	ELME000482	0	0	0	2	2	2	0	0	0	0	0	0.3	
LIG_Pex14_1	ELME000080	1	0	0	0	1	0	0	0	2	2	0	0.4	
LIG_Pex14_2	ELME000328	2	3	1	2	0	2	1	1	1	2	1	0.9	
LIG_PTB_Apo_2	ELME000122	0	0	0	2	1	0	1	1	1	1	0	0.5	
LIG_PTB_Phospho_1	ELME000095	0	0	0	1	1	0	1	1	0	0	0	0.4	
LIG_REV1ctd_RIR_1	ELME000450	0	0	0	0	0	0	0	0	1	0	0	0.1	
LIG_RPA_C_Fungi	ELME000382	0	0	0	0	0	0	1	1	0	1	0	0.3	
LIG_SH2_CRK	ELME000458	0	1	0	1	2	2	0	0	1	1	0	0.5	
LIG_SH2_GRB2like	ELME000084	0	0	0	0	0	0	0	0	0	0	1	0.1	
LIG_SH2_NCK_1	ELME000474	0	1	0	1	0	1	0	0	1	1	0	0.5	
LIG_SH2_PTP2	ELME000083	1	0	1	1	1	0	1	1	1	0	1	0.7	
LIG_SH2_SRC	ELME000081	1	0	2	1	1	1	1	1	1	0	2	0.8	
LIG_SH2_STAP1	ELME000465	2	1	0	0	1	1	0	0	1	1	1	0.6	
LIG_SH2_STAT3	ELME000163	2	2	1	0	1	1	1	1	0	0	1	0.7	
LIG_SH2_STAT5	ELME000182	3	1	3	2	3	2	3	3	3	2	5	1.0	
LIG_SH3_3	ELME000155	1	2	1	1	3	2	1	1	5	4	2	1.0	
LIG_SUMO_SIM_par_1	ELME000333	0	1	0	1	0	0	0	0	1	2	0	0.4	
LIG_SxIP_EBH_1	ELME000254	1	0	1	2	0	1	0	2	0	1	1	0.6	
LIG_TRAF2_1	ELME000117	1	1	0	1	1	2	1	1	0	0	0	0.6	
LIG_TRAF6	ELME000133	0	0	0	0	0	1	0	0	0	0	0	0.1	
LIG_TRFH_1	ELME000249	0	0	0	0	0	0	0	0	0	0	1	0.1	
LIG_TYR_ITIM	ELME000020	1	0	2	1	1	0	1	1	1	0	1	0.7	
LIG_UBA3_1	ELME000395	0	0	1	0	0	0	0	0	0	0	1	0.2	
LIG_Vh1_VBS_1	ELME000438	0	0	0	1	0	0	1	1	0	1	0	0.4	
LIG_WD40_WDR5_VDV_1	ELME000364	0	0	0	0	0	0	0	0	0	1	0	0.1	
LIG_WD40_WDR5_VDV_2	ELME000365	2	10	6	5	6	8	8	8	10	10	12	1.0	
LIG_WW_3	ELME000135	0	0	0	1	0	0	0	0	0	0	0	0.1	
Modification	MOD_CDK_SPK_2	ELME000429	0	0	1	0	1	0	0	0	0	0	1	0.3	
MOD_CDK_SPxxK_3	ELME000428	0	0	0	0	1	1	0	0	1	1	0	0.4	
MOD_CK1_1	ELME000063	1	0	1	2	3	1	3	3	4	3	3	0.9	
MOD_CK2_1	ELME000064	3	2	1	4	3	2	0	0	0	1	0	0.6	
MOD_CMANNOS	ELME000160	0	0	0	0	1	0	0	0	0	0	0	0.1	
MOD_Cter_Amidation	ELME000093	1	1	0	0	0	0	0	0	0	0	0	0.2	
MOD_GlcNHglycan	ELME000085	1	3	3	3	2	0	2	2	4	2	5	0.9	
MOD_GSK3_1	ELME000053	3	1	3	4	2	2	1	1	0	4	6	0.9	
MOD_NEK2_1	ELME000336	2	3	3	2	2	1	4	4	1	2	3	1.0	
MOD_NEK2_2	ELME000337	0	0	1	1	1	1	0	0	1	0	1	0.5	
MOD_N-GLC_1	ELME000070	3	0	0	2	1	1	0	0	2	1	1	0.6	
MOD_N-GLC_2	ELME000079	0	0	1	0	2	0	0	0	0	0	1	0.3	
MOD_PIKK_1	ELME000202	5	3	2	1	2	0	0	0	2	1	0	0.6	
MOD_PK_1	ELME000065	0	2	0	0	0	1	0	0	0	0	1	0.3	
MOD_PKA_1	ELME000008	0	1	0	1	0	1	0	0	0	1	0	0.4	
MOD_PKA_2	ELME000062	1	1	1	1	1	2	0	2	1	0	2	0.8	
MOD_Plk_1	ELME000442	4	2	1	2	2	4	1	1	2	3	2	1.0	
MOD_Plk_4	ELME000444	1	2	3	2	2	2	0	0	1	2	0	0.7	
MOD_ProDKin_1	ELME000159	3	3	1	0	6	2	2	2	3	3	1	0.9	
MOD_SUMO_for_1	ELME000002	0	0	0	0	0	0	0	0	2	0	0	0.1	
MOD_SUMO_rev_2	ELME000393	1	1	0	0	0	0	0	0	0	0	0	0.2	
Targeting	TRG_ENDOCYTIC_2	ELME000120	2	1	3	2	2	2	1	1	2	1	2	1.0	
TRG_LysEnd_APsAcLL_1	ELME000149	0	0	0	0	0	0	0	0	1	0	1	0.2	
TRG_NLS_MonoExtC_3	ELME000278	0	0	0	0	0	1	0	0	0	0	0	0.1	
TRG_Pf-PMV_PEXEL_1	ELME000462	1	1	1	1	1	1	1	1	1	1	1	1.0	
GenBank accession numbers for endogenous integrase sequences are as follows: Endogenous retrovirus-K (ERVK in Homo sapiens; P10266.2), ERVK-8 pol protein-like (Macaca fascicularis; XP_015309771.1), Pol protein (Chlorocebus sabaeus; KFO35018.1), Pol protein (Fukomys darmarensis; BBC20786.1), Putative protein (Ochonta princeps; XP_012786727.1), ERVK-8 pol protein-like (Equus asinus; XP_014715024.1), ERVK-18 pol protein-like (Capra hircus; XP_017905435.1), Pol protein (Ovis aries; ABV71120.1), Putative protein (Zonotrichia albicollis; TRZ15504.1), Putative protein (Zosterops borbonicus; XP_014125095.1), Integrase (Onchocerca flexuosa; OZC05619.1).

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Christiaansen A. Varga S.M. Spencer J.V. Viral manipulation of the host immune response Curr. Opin. Immunol. 2015 36 54 60 10.1016/j.coi.2015.06.012 26177523
2. McLean J.E. Ruck A. Shirazian A. Pooyaei-Mehr F. Zakeri Z.F. Viral manipulation of cell death Curr. Pharm. Des. 2008 14 198 220 10.2174/138161208783413329 18220831
3. Garcia-Etxebarria K. Sistiaga-Poveda M. Jugo B.M. Endogenous retroviruses in domestic animals Curr. Genom. 2014 15 256 265 10.2174/1389202915666140520003503 25132796
4. Xu X. Zhao H. Gong Z. Han G.Z. Endogenous retroviruses of non-avian/mammalian vertebrates illuminate diversity and deep history of retroviruses PLoS Pathog. 2018 14 e1007072 10.1371/journal.ppat.1007072 29902269
5. Nelson P.N. Carnegie P.R. Martin J. Davari Ejtehadi H. Hooley P. Roden D. Rowland-Jones S. Warren P. Astley J. Murray P.G. Demystified. Human endogenous retroviruses Mol. Pathol. 2003 56 11 18 10.1136/mp.56.1.11 12560456
6. Mayer J. Meese E. Human endogenous retroviruses in the primate lineage and their influence on host genomes Cytogenet. Genome Res. 2005 110 448 456 10.1159/000084977 16093697
7. Hohn O. Hanke K. Bannert N. HERV-K(HML-2), the Best Preserved Family of HERVs: Endogenization, Expression, and Implications in Health and Disease Front. Oncol. 2013 3 246 10.3389/fonc.2013.00246 24066280
8. Downey R.F. Sullivan F.J. Wang-Johanning F. Ambs S. Giles F.J. Glynn S.A. Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice? Int. J. Cancer 2015 137 1249 1257 10.1002/ijc.29003 24890612
9. Douville R. Liu J. Rothstein J. Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis Ann. Neurol. 2011 69 141 151 10.1002/ana.22149 21280084
10. Manghera M. Ferguson-Parry J. Douville R.N. TDP-43 regulates endogenous retrovirus-K viral protein accumulation Neurobiol. Dis. 2016 94 226 236 10.1016/j.nbd.2016.06.017 27370226
11. Manghera M. Ferguson-Parry J. Lin R. Douville R.N. NF-kappaB and IRF1 Induce Endogenous Retrovirus K Expression via Interferon-Stimulated Response Elements in Its 5′ Long Terminal Repeat J. Virol. 2016 90 9338 9349 10.1128/JVI.01503-16 27512062
12. Arru G. Mameli G. Deiana G.A. Rassu A.L. Piredda R. Sechi E. Caggiu E. Bo M. Nako E. Urso D. Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases Eur. J. Neurol. 2018 25 e1076 e1084 10.1111/ene.13648 29603839
13. Romer C. Viruses and Endogenous Retroviruses as Roots for Neuroinflammation and Neurodegenerative Diseases Front. Neurosci. 2021 15 648629 10.3389/fnins.2021.648629 33776642
14. Greenig M. HERVs, immunity, and autoimmunity: Understanding the connection PeerJ 2019 7 e6711 10.7717/peerj.6711 30984482
15. Vincendeau M. Gottesdorfer I. Schreml J.M. Wetie A.G. Mayer J. Greenwood A.D. Helfer M. Kramer S. Seifarth W. Hadian K. Modulation of human endogenous retrovirus (HERV) transcription during persistent and de novo HIV-1 infection Retrovirology 2015 12 27 10.1186/s12977-015-0156-6 25886562
16. Pilie P.G. Tang C. Mills G.B. Yap T.A. State-of-the-art strategies for targeting the DNA damage response in cancer Nat. Rev. Clin. Oncol. 2019 16 81 104 10.1038/s41571-018-0114-z 30356138
17. Penndorf D. Witte O.W. Kretz A. DNA plasticity and damage in amyotrophic lateral sclerosis Neural Regen. Res. 2018 13 173 180 10.4103/1673-5374.226377 29557356
18. Gao F.B. Almeida S. Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder EMBO J. 2017 36 2931 2950 10.15252/embj.201797568 28916614
19. Kessl J.J. Kutluay S.B. Townsend D. Rebensburg S. Slaughter A. Larue R.C. Shkriabai N. Bakouche N. Fuchs J.R. Bieniasz P.D. HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis Cell 2016 166 1257 1268.e1212 10.1016/j.cell.2016.07.044 27565348
20. Lesbats P. Engelman A.N. Cherepanov P. Retroviral DNA Integration Chem. Rev. 2016 116 12730 12757 10.1021/acs.chemrev.6b00125 27198982
21. Daniel R. Kao G. Taganov K. Greger J.G. Favorova O. Merkel G. Yen T.J. Katz R.A. Skalka A.M. Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response Proc. Natl. Acad. Sci. USA 2003 100 4778 4783 10.1073/pnas.0730887100 12679521
22. Skalka A.M. Katz R.A. Retroviral DNA integration and the DNA damage response Cell Death Differ. 2005 12 Suppl. S1 971 978 10.1038/sj.cdd.4401573 15761474
23. Bray S. Turnbull M. Hebert S. Douville R.N. Insight into the ERVK Integrase—Propensity for DNA Damage Front. Microbiol. 2016 7 1941 10.3389/fmicb.2016.01941 27990140
24. Kitamura Y. Ayukawa T. Ishikawa T. Kanda T. Yoshiike K. Human endogenous retrovirus K10 encodes a functional integrase J. Virol. 1996 70 3302 3306 10.1128/jvi.70.5.3302-3306.1996 8627815
25. Van Maele B. Busschots K. Vandekerckhove L. Christ F. Debyser Z. Cellular co-factors of HIV-1 integration Trends Biochem. Sci. 2006 31 98 105 10.1016/j.tibs.2005.12.002 16403635
26. Christ F. Debyser Z. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy Virology 2013 435 102 109 10.1016/j.virol.2012.09.033 23217620
27. Studamire B. Goff S.P. Interactions of host proteins with the murine leukemia virus integrase Viruses 2010 2 1110 1145 10.3390/v2051110 21637732
28. Jayappa K.D. Ao Z. Wang X. Mouland A.J. Shekhar S. Yang X. Yao X. Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein J. Virol. 2015 89 3497 3511 10.1128/JVI.03347-14 25568209
29. Ryan E.L. Hollingworth R. Grand R.J. Activation of the DNA Damage Response by RNA Viruses Biomolecules 2016 6 2 10.3390/biom6010002 26751489
30. Suzuki Y. Craigie R. The road to chromatin—Nuclear entry of retroviruses Nat. Rev. Microbiol. 2007 5 187 196 10.1038/nrmicro1579 17304248
31. Suzuki Y. Chew M.L. Role of host-encoded proteins in restriction of retroviral integration Front. Microbiol. 2012 3 227 10.3389/fmicb.2012.00227 22737148
32. Daniel R. Greger J.G. Katz R.A. Taganov K.D. Wu X. Kappes J.C. Skalka A.M. Evidence that stable retroviral transduction and cell survival following DNA integration depend on components of the nonhomologous end joining repair pathway J. Virol. 2004 78 8573 8581 10.1128/JVI.78.16.8573-8581.2004 15280466
33. Turlure F. Devroe E. Silver P.A. Engelman A. Human cell proteins and human immunodeficiency virus DNA integration Front. Biosci. 2004 9 3187 3208 10.2741/1472 15353349
34. Cooper A. Garcia M. Petrovas C. Yamamoto T. Koup R.A. Nabel G.J. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration Nature 2013 498 376 379 10.1038/nature12274 23739328
35. Hanahan D. Weinberg R.A. Hallmarks of cancer: The next generation Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
36. Mourad R. Ginalski K. Legube G. Cuvier O. Predicting double-strand DNA breaks using epigenome marks or DNA at kilobase resolution Genome Biol. 2018 19 34 10.1186/s13059-018-1411-7 29544533
37. Stetson D.B. Ko J.S. Heidmann T. Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity Cell 2008 134 587 598 10.1016/j.cell.2008.06.032 18724932
38. Zhang J. Scadden D.T. Crumpacker C.S. Primitive hematopoietic cells resist HIV-1 infection via p21 J. Clin. Investig. 2007 117 473 481 10.1172/JCI28971 17273559
39. Ran X. Ao Z. Olukitibi T. Yao X. Characterization of the Role of Host Cellular Factor Histone Deacetylase 10 during HIV-1 Replication Viruses 2019 12 28 10.3390/v12010028
40. Ali H. Mano M. Braga L. Naseem A. Marini B. Vu D.M. Collesi C. Meroni G. Lusic M. Giacca M. Cellular TRIM33 restrains HIV-1 infection by targeting viral integrase for proteasomal degradation Nat. Commun. 2019 10 926 10.1038/s41467-019-08810-0 30804369
41. Mulder L.C. Chakrabarti L.A. Muesing M.A. Interaction of HIV-1 integrase with DNA repair protein hRad18 J. Biol. Chem. 2002 277 27489 27493 10.1074/jbc.M203061200 12016221
42. Van Maele B. Debyser Z. HIV-1 integration: An interplay between HIV-1 integrase, cellular and viral proteins AIDS Rev. 2005 7 26 43 15875659
43. Anisenko A.N. Knyazhanskaya E.S. Zalevsky A.O. Agapkina J.Y. Sizov A.I. Zatsepin T.S. Gottikh M.B. Characterization of HIV-1 integrase interaction with human Ku70 protein and initial implications for drug targeting Sci. Rep. 2017 7 5649 10.1038/s41598-017-05659-5 28717247
44. BLAST Available online: https://www.ncbi.nlm.nih.gov/BLAST/ (accessed on 12 July 2021)
45. Rosindell J. Harmon L.J. OneZoom: A fractal explorer for the tree of life PLoS Biol. 2012 10 e1001406 10.1371/journal.pbio.1001406 23091419
46. Kearse M. Moir R. Wilson A. Stones-Havas S. Cheung M. Sturrock S. Buxton S. Cooper A. Markowitz S. Duran C. Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data Bioinformatics 2012 28 1647 1649 10.1093/bioinformatics/bts199 22543367
47. Lu S. Wang J. Chitsaz F. Derbyshire M.K. Geer R.C. Gonzales N.R. Gwadz M. Hurwitz D.I. Marchler G.H. Song J.S. CDD/SPARCLE: The conserved domain database in 2020 Nucleic Acids Res. 2020 48 D265 D268 10.1093/nar/gkz991 31777944
48. Kumar M. Gouw M. Michael S. Sámano-Sánchez H. Pancsa R. Glavina J. Diakogianni A. Valverde J.A. Bukirova D. Čalyševa J. ELM-the eukaryotic linear motif resource in 2020 Nucleic Acids Res. 2020 48 D296 D306 10.1093/nar/gkz1030 31680160
49. Lee Y.M. Liou Y.C. Gears-In-Motion: The Interplay of WW and PPIase Domains in Pin1 Front. Oncol. 2018 8 469 10.3389/fonc.2018.00469 30460195
50. Ramos F. Villoria M.T. Alonso-Rodriguez E. Clemente-Blanco A. Role of protein phosphatases PP1, PP2A, PP4 and Cdc14 in the DNA damage response Cell Stress 2019 3 70 85 10.15698/cst2019.03.178 31225502
51. Knippschild U. Kruger M. Richter J. Xu P. Garcia-Reyes B. Peifer C. Halekotte J. Bakulev V. Bischof J. The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis Front. Oncol. 2014 4 96 10.3389/fonc.2014.00096 24904820
52. Fry A.M. O’Regan L. Sabir S.R. Bayliss R. Cell cycle regulation by the NEK family of protein kinases J. Cell Sci. 2012 125 4423 4433 10.1242/jcs.111195 23132929
53. Kumar S. Sharma G. Chakraborty C. Sharma A.R. Kim J. Regulatory functional territory of PLK-1 and their substrates beyond mitosis Oncotarget 2017 8 37942 37962 10.18632/oncotarget.16290 28415805
54. Reinhardt H.C. Yaffe M.B. Phospho-Ser/Thr-binding domains: Navigating the cell cycle and DNA damage response Nat. Rev. Mol. Cell Biol. 2013 14 563 580 10.1038/nrm3640 23969844
55. Chang Z. Wang Y. Zhou X. Long J.E. STAT3 roles in viral infection: Antiviral or proviral? Future Virol. 2018 13 557 574 10.2217/fvl-2018-0033 32201498
56. Rani A. Murphy J.J. STAT5 in Cancer and Immunity J. Interferon Cytokine Res. 2016 36 226 237 10.1089/jir.2015.0054 26716518
57. Mahajan K. Mahajan N.P. Cross talk of tyrosine kinases with the DNA damage signaling pathways Nucleic Acids Res. 2015 43 10588 10601 10.1093/nar/gkv1166 26546517
58. Teyra J. Huang H. Jain S. Guan X. Dong A. Liu Y. Tempel W. Min J. Tong Y. Kim P.M. Comprehensive Analysis of the Human SH3 Domain Family Reveals a Wide Variety of Non-canonical Specificities Structure 2017 25 1598 1610.e3 10.1016/j.str.2017.07.017 28890361
59. Lalaoui N. Vaux D.L. Recent advances in understanding inhibitor of apoptosis proteins F1000Research 2018 7 10.12688/f1000research.16439.1
60. Liu H. Li L. Voss C. Wang F. Liu J. Li S.S. A Comprehensive Immunoreceptor Phosphotyrosine-based Signaling Network Revealed by Reciprocal Protein-Peptide Array Screening Mol. Cell Proteom. 2015 14 1846 1858 10.1074/mcp.M115.047951 25907764
61. Beurel E. Grieco S.F. Jope R.S. Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases Pharmacol. Ther. 2015 148 114 131 10.1016/j.pharmthera.2014.11.016 25435019
62. Canovas B. Nebreda A.R. Diversity and versatility of p38 kinase signalling in health and disease Nat. Rev. Mol. Cell Biol. 2021 22 346 366 10.1038/s41580-020-00322-w 33504982
63. Covill-Cooke C. Toncheva V.S. Kittler J.T. Regulation of peroxisomal trafficking and distribution Cell. Mol. Life Sci. 2021 78 1929 1941 10.1007/s00018-020-03687-5 33141311
64. Kumar P. Wittmann T. + TIPs: SxIPping along microtubule ends Trends Cell Biol. 2012 22 418 428 10.1016/j.tcb.2012.05.005 22748381
65. Park S.Y. Guo X. Adaptor protein complexes and intracellular transport Biosci. Rep. 2014 34 10.1042/BSR20140069
66. Egea P.F. Crossing the Vacuolar Rubicon: Structural Insights into Effector Protein Trafficking in Apicomplexan Parasites Microorganisms 2020 8 865 10.3390/microorganisms8060865 32521667
67. Matic I. Schimmel J. Hendriks I.A. van Santen M.A. van de Rijke F. van Dam H. Gnad F. Mann M. Vertegaal A.C. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif Mol. Cell 2010 39 641 652 10.1016/j.molcel.2010.07.026 20797634
68. Zamborlini A. Coiffic A. Beauclair G. Delelis O. Paris J. Koh Y. Magne F. Giron M.L. Tobaly-Tapiero J. Deprez E. Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect J. Biol. Chem. 2011 286 21013 21022 10.1074/jbc.M110.189274 21454548
69. Zhao X. SUMO-Mediated Regulation of Nuclear Functions and Signaling Processes Mol. Cell 2018 71 409 418 10.1016/j.molcel.2018.07.027 30075142
70. Quek H. Lim Y.C. Lavin M.F. Roberts T.L. PIKKing a way to regulate inflammation Immunol. Cell Biol. 2018 96 8 20 10.1111/imcb.1001 29359354
71. Penalosa-Ruiz G. Bousgouni V. Gerlach J.P. Waarlo S. van de Ven J.V. Veenstra T.E. Silva J.C.R. van Heeringen S.J. Bakal C. Mulder K.W. WDR5, BRCA1, and BARD1 Co-regulate the DNA Damage Response and Modulate the Mesenchymal-to-Epithelial Transition during Early Reprogramming Stem Cell Rep. 2019 12 743 756 10.1016/j.stemcr.2019.02.006 30880078
72. Wheatley S.P. Altieri D.C. Survivin at a glance J. Cell Sci. 2019 132 10.1242/jcs.223826 30948431
73. Fang Y. Zhang X. Targeting NEK2 as a promising therapeutic approach for cancer treatment Cell Cycle 2016 15 895 907 10.1080/15384101.2016.1152430 27019372
74. De Carcer G. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor? Genes 2019 10 208 10.3390/genes10030208 30862113
75. Van Grevenynghe J. Cubas R.A. DaFonseca S. Metcalf T. Tremblay C.L. Trautmann L. Sekaly R.P. Schatzle J. Haddad E.K. Foxo3a: An integrator of immune dysfunction during HIV infection Cytokine Growth Factor Rev. 2012 23 215 221 10.1016/j.cytogfr.2012.05.008 22748238
76. Aloni-Grinstein R. Charni-Natan M. Solomon H. Rotter V. p53 and the Viral Connection: Back into the Future (double dagger) Cancers 2018 10 178 10.3390/cancers10060178
77. Ho J. Moyes D.L. Tavassoli M. Naglik J.R. The Role of ErbB Receptors in Infection Trends Microbiol. 2017 25 942 952 10.1016/j.tim.2017.04.009 28522156
78. Khanizadeh S. Hasanvand B. Esmaeil Lashgarian H. Almasian M. Goudarzi G. Interaction of viral oncogenic proteins with the Wnt signaling pathway Iran. J. Basic Med. Sci. 2018 21 651 659 10.22038/IJBMS.2018.28903.6982 30140402
79. De Martini W. Rahman R. Ojegba E. Jungwirth E. Macias J. Ackerly F. Fowler M. Cottrell J. Chu T. Chang S.L. Kinases: Understanding Their Role in HIV Infection World J. AIDS 2019 9 142 160 10.4236/wja.2019.93011 32257606
80. Medders K.E. Kaul M. Mitogen-activated protein kinase p38 in HIV infection and associated brain injury J. Neuroimmune Pharmacol. 2011 6 202 215 10.1007/s11481-011-9260-0 21286833
81. Saez-Cirion A. Manel N. Immune Responses to Retroviruses Annu. Rev. Immunol. 2018 36 193 220 10.1146/annurev-immunol-051116-052155 29328787
82. Shi J.H. Sun S.C. Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor kappaB and Mitogen-Activated Protein Kinase Pathways Front. Immunol. 2018 9 1849 10.3389/fimmu.2018.01849 30140268
83. Nehlig A. Molina A. Rodrigues-Ferreira S. Honore S. Nahmias C. Regulation of end-binding protein EB1 in the control of microtubule dynamics Cell. Mol. Life Sci. 2017 74 2381 2393 10.1007/s00018-017-2476-2 28204846
84. Cao H. Orth J.D. Chen J. Weller S.G. Heuser J.E. McNiven M.A. Cortactin is a component of clathrin-coated pits and participates in receptor-mediated endocytosis Mol. Cell. Biol. 2003 23 2162 2170 10.1128/MCB.23.6.2162-2170.2003 12612086
85. Zare M. Mostafaei S. Ahmadi A. Azimzadeh Jamalkandi S. Abedini A. Esfahani-Monfared Z. Dorostkar R. Saadati M. Human endogenous retrovirus env genes: Potential blood biomarkers in lung cancer Microb. Pathog. 2018 115 189 193 10.1016/j.micpath.2017.12.040 29274460
86. Bergallo M. Montanari P. Mareschi K. Merlino C. Berger M. Bini I. Dapra V. Galliano I. Fagioli F. Expression of the pol gene of human endogenous retroviruses HERV-K and -W in leukemia patients Arch. Virol 2017 162 3639 3644 10.1007/s00705-017-3526-7 28821995
87. Ma W. Hong Z. Liu H. Chen X. Ding L. Liu Z. Zhou F. Yuan Y. Human Endogenous Retroviruses-K (HML-2) Expression Is Correlated with Prognosis and Progress of Hepatocellular Carcinoma BioMed Res. Int. 2016 2016 8201642 10.1155/2016/8201642 28070518
88. Yuan Z. Yang Y. Zhang N. Soto C. Jiang X. An Z. Zheng W.J. Human Endogenous Retroviruses in Glioblastoma Multiforme Microorganisms 2021 9 764 10.3390/microorganisms9040764 33917421
89. Dembny P. Newman A.G. Singh M. Hinz M. Szczepek M. Kruger C. Adalbert R. Dzaye O. Trimbuch T. Wallach T. Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors JCI Insight 2020 5 10.1172/jci.insight.131093
90. Jeong B.H. Lee Y.J. Carp R.I. Kim Y.S. The prevalence of human endogenous retroviruses in cerebrospinal fluids from patients with sporadic Creutzfeldt-Jakob disease J. Clin. Virol. 2010 47 136 142 10.1016/j.jcv.2009.11.016 20005155
91. Tovo P.A. Rabbone I. Tinti D. Galliano I. Trada M. Dapra V. Cerutti F. Bergallo M. Enhanced expression of human endogenous retroviruses in new-onset type 1 diabetes: Potential pathogenetic and therapeutic implications Autoimmunity 2020 53 283 288 10.1080/08916934.2020.1777281 32586158
92. Mason M.J. Speake C. Gersuk V.H. Nguyen Q.A. O’Brien K.K. Odegard J.M. Buckner J.H. Greenbaum C.J. Chaussabel D. Nepom G.T. Low HERV-K(C4) copy number is associated with type 1 diabetes Diabetes 2014 63 1789 1795 10.2337/db13-1382 24430436
93. Dickerson F. Rubalcaba E. Viscidi R. Yang S. Stallings C. Sullens A. Origoni A. Leister F. Yolken R. Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia Schizophr. Res. 2008 104 121 126 10.1016/j.schres.2008.05.005 18617371
94. Cinek O. Kramna L. Odeh R. Alassaf A. Ibekwe M.A.U. Ahmadov G. Elmahi B.M.E. Mekki H. Lebl J. Abdullah M.A. Eukaryotic viruses in the fecal virome at the onset of type 1 diabetes: A study from four geographically distant African and Asian countries Pediatr. Diabetes 2021 22 558 566 10.1111/pedi.13207 33786936
95. Piekna-Przybylska D. Sharma G. Maggirwar S.B. Bambara R.A. Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1 Cell Cycle 2017 16 968 978 10.1080/15384101.2017.1312225 28388353
96. Li D. Lopez A. Sandoval C. Nichols Doyle R. Fregoso O.I. HIV Vpr Modulates the Host DNA Damage Response at Two Independent Steps to Damage DNA and Repress Double-Strand DNA Break Repair mBio 2020 11 10.1128/mBio.00940-20
97. Zhi H. Guo X. Ho Y.K. Pasupala N. Engstrom H.A.A. Semmes O.J. Giam C.Z. RNF8 Dysregulation and Down-regulation During HTLV-1 Infection Promote Genomic Instability in Adult T-Cell Leukemia PLoS Pathog. 2020 16 e1008618 10.1371/journal.ppat.1008618 32453758
98. Luftig M.A. Viruses and the DNA Damage Response: Activation and Antagonism Annu. Rev. Virol. 2014 1 605 625 10.1146/annurev-virology-031413-085548 26958736
99. Hristova D.B. Lauer K.B. Ferguson B.J. Viral interactions with non-homologous end-joining: A game of hide-and-seek J. Gen. Virol. 2020 101 1133 1144 10.1099/jgv.0.001478 32735206
100. Mohammad D.H. Yaffe M.B. 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response DNA Repair 2009 8 1009 1017 10.1016/j.dnarep.2009.04.004 19481982
101. Pancholi N.J. Price A.M. Weitzman M.D. Take your PIKK: Tumour viruses and DNA damage response pathways Philos. Trans. R. Soc. Lond. B Biol. Sci. 2017 372 10.1098/rstb.2016.0269
102. Zimmerman E.S. Chen J. Andersen J.L. Ardon O. Dehart J.L. Blackett J. Choudhary S.K. Camerini D. Nghiem P. Planelles V. Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation Mol. Cell. Biol. 2004 24 9286 9294 10.1128/MCB.24.21.9286-9294.2004 15485898
103. Shukrun M. Jabareen A. Abou-Kandil A. Chamias R. Aboud M. Huleihel M. HTLV-1 Tax oncoprotein inhibits the estrogen-induced-ER alpha-Mediated BRCA1 expression by interaction with CBP/p300 cofactors PLoS ONE 2014 9 e89390 10.1371/journal.pone.0089390 24586743
104. Nathan K.G. Lal S.K. The Multifarious Role of 14-3-3 Family of Proteins in Viral Replication Viruses 2020 12 436 10.3390/v12040436 32294919
105. Wu Q. Jubb H. Blundell T.L. Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif Prog. Biophys. Mol. Biol. 2015 117 143 148 10.1016/j.pbiomolbio.2015.02.003 25701377
106. Clapperton J.A. Manke I.A. Lowery D.M. Ho T. Haire L.F. Yaffe M.B. Smerdon S.J. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer Nat. Struct. Mol. Biol. 2004 11 512 518 10.1038/nsmb775 15133502
107. Fan X. Cui L. Zeng Y. Song W. Gaur U. Yang M. 14-3-3 Proteins Are on the Crossroads of Cancer, Aging, and Age-Related Neurodegenerative Disease Int. J. Mol. Sci. 2019 20 3518 10.3390/ijms20143518
108. Morales D. Skoulakis E.C. Acevedo S.F. 14-3-3s are potential biomarkers for HIV-related neurodegeneration J. Neurovirol. 2012 18 341 353 10.1007/s13365-012-0121-2 22811265
109. Roskoski R. Jr. RAF protein-serine/threonine kinases: Structure and regulation Biochem. Biophys. Res. Commun. 2010 399 313 317 10.1016/j.bbrc.2010.07.092 20674547
110. Tang J. Wang J.Y. Parker L.L. Detection of early Abl kinase activation after ionizing radiation by using a peptide biosensor ChemBioChem Eur. J. Chem. Biol. 2012 13 665 673 10.1002/cbic.201100763
111. McCarthy S.D.S. Leontyev D. Nicoletti P. Binnington B. Kozlowski H.N. Ostrowski M. Cochrane A. Branch D.R. Wong R.W. Targeting ABL1 or ARG Tyrosine Kinases to Restrict HIV-1 Infection in Primary CD4+ T-Cells or in Humanized NSG Mice J. Acquir. Immune Defic. Syndr. 2019 82 407 415 10.1097/QAI.0000000000002144 31658184
112. Kodama D. Tanaka M. Matsuzaki T. Izumo K. Nakano N. Matsuura E. Saito M. Nagai M. Horiuchi M. Utsunomiya A. Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis PLoS Negl. Trop. Dis. 2020 14 e0008361 10.1371/journal.pntd.0008361 32667912
113. Baskaran R. Escobar S.R. Wang J.Y. Nuclear c-Abl is a COOH-terminal repeated domain (CTD)-tyrosine (CTD)-tyrosine kinase-specific for the mammalian RNA polymerase II: Possible role in transcription elongation Cell Growth Differ. 1999 10 387 396 10392900
114. Schlatterer S.D. Acker C.M. Davies P. c-Abl in neurodegenerative disease J. Mol. Neurosci. 2011 45 445 452 10.1007/s12031-011-9588-1 21728062
115. Kim B.W. Jeong Y.E. Wong M. Martin L.J. DNA damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in iPSC-derived motor neurons with SOD1 mutations Acta Neuropathol. Commun. 2020 8 7 10.1186/s40478-019-0874-4 32005289
116. Wang W. Mani A.M. Wu Z.H. DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression J. Cancer Metastasis Treat. 2017 3 45 59 10.20517/2394-4722.2017.03 28626800
117. Zuo S. Xue Y. Tang S. Yao J. Du R. Yang P. Chen X. 14-3-3 epsilon dynamically interacts with key components of mitogen-activated protein kinase signal module for selective modulation of the TNF-alpha-induced time course-dependent NF-kappaB activity J. Proteome Res. 2010 9 3465 3478 10.1021/pr9011377 20462248
118. Pennington K.L. Chan T.Y. Torres M.P. Andersen J.L. The dynamic and stress-adaptive signaling hub of 14-3-3: Emerging mechanisms of regulation and context-dependent protein-protein interactions Oncogene 2018 37 5587 5604 10.1038/s41388-018-0348-3 29915393
119. Saha R.N. Jana M. Pahan K. MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65 J. Immunol. 2007 179 7101 7109 10.4049/jimmunol.179.10.7101 17982102
120. Zheng Y. Ao Z. Wang B. Jayappa K.D. Yao X. Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication J. Biol. Chem. 2011 286 17722 17735 10.1074/jbc.M110.184739 21454661
121. Llano M. Delgado S. Vanegas M. Poeschla E.M. Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase J. Biol. Chem. 2004 279 55570 55577 10.1074/jbc.M408508200 15475359
122. Manganaro L. Lusic M. Gutierrez M.I. Cereseto A. Del Sal G. Giacca M. Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes Nat. Med. 2010 16 329 333 10.1038/nm.2102 20173753
123. Quy V.C. Carnevale V. Manganaro L. Lusic M. Rossetti G. Leone V. Fenollar-Ferrer C. Raugei S. Del Sal G. Giacca M. HIV-1 integrase binding to its cellular partners: A perspective from computational biology Curr. Pharm. Des. 2014 20 3412 3421 10.2174/13816128113199990631 24001231
124. Kojima Y. Ryo A. Pinning down viral proteins: A new prototype for virus-host cell interaction Front. Microbiol. 2010 1 107 10.3389/fmicb.2010.00107 21738521
125. Nieto-Torres J.L. Leidal A.M. Debnath J. Hansen M. Beyond Autophagy: The Expanding Roles of ATG8 Proteins Trends Biochem. Sci. 2021 10.1016/j.tibs.2021.01.004 33558127
126. Leymarie O. Lepont L. Berlioz-Torrent C. Canonical and Non-Canonical Autophagy in HIV-1 Replication Cycle Viruses 2017 9 270 10.3390/v9100270 28946621
127. Vicencio E. Beltran S. Labrador L. Manque P. Nassif M. Woehlbier U. Implications of Selective Autophagy Dysfunction for ALS Pathology Cells 2020 9 381 10.3390/cells9020381
128. Watanabe Y. Taguchi K. Tanaka M. Ubiquitin, Autophagy and Neurodegenerative Diseases Cells 2020 9 2022 10.3390/cells9092022
129. Negrini S. Gorgoulis V.G. Halazonetis T.D. Genomic instability--an evolving hallmark of cancer Nat. Rev. Mol. Cell Biol. 2010 11 220 228 10.1038/nrm2858 20177397
130. Sun Y. Curle A.J. Haider A.M. Balmus G. The role of DNA damage response in amyotrophic lateral sclerosis Essays Biochem. 2020 64 847 861 10.1042/EBC20200002 33078197
131. Hou Y. Song H. Croteau D.L. Akbari M. Bohr V.A. Genome instability in Alzheimer disease Mech. Ageing Dev. 2017 161 83 94 10.1016/j.mad.2016.04.005 27105872
132. Madabhushi R. Pan L. Tsai L.H. DNA damage and its links to neurodegeneration Neuron 2014 83 266 282 10.1016/j.neuron.2014.06.034 25033177
133. Malaspina A. Kaushik N. de Belleroche J. A 14-3-3 mRNA is up-regulated in amyotrophic lateral sclerosis spinal cord J. Neurochem. 2000 75 2511 2520 10.1046/j.1471-4159.2000.0752511.x 11080204
134. Hermeking H. The 14-3-3 cancer connection Nat. Rev. Cancer 2003 3 931 943 10.1038/nrc1230 14737123
135. Martin L.J. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis Neurobiol. Dis. 2000 7 613 622 10.1006/nbdi.2000.0314 11114260
136. Ozaki T. Nakagawara A. Role of p53 in Cell Death and Human Cancers Cancers 2011 3 994 1013 10.3390/cancers3010994 24212651
137. Koul H.K. Pal M. Koul S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors Genes Cancer 2013 4 342 359 10.1177/1947601913507951 24349632
138. Guo W. Vandoorne T. Steyaert J. Staats K.A. Van Den Bosch L. The multifaceted role of kinases in amyotrophic lateral sclerosis: Genetic, pathological and therapeutic implications Brain 2020 143 1651 1673 10.1093/brain/awaa022 32206784
139. Jiang X. Guan Y. Zhao Z. Meng F. Wang X. Gao X. Liu J. Chen Y. Zhou F. Zhou S. Potential Roles of the WNT Signaling Pathway in Amyotrophic Lateral Sclerosis Cells 2021 10 839 10.3390/cells10040839 33917816
140. Menck K. Heinrichs S. Baden C. Bleckmann A. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention Cells 2021 10 142 10.3390/cells10010142 33445713
141. Manigrasso M.B. Juranek J. Ramasamy R. Schmidt A.M. Unlocking the biology of RAGE in diabetic microvascular complications Trends Endocrinol. Metab. 2014 25 15 22 10.1016/j.tem.2013.08.002 24011512
142. Kumar V. Fleming T. Terjung S. Gorzelanny C. Gebhardt C. Agrawal R. Mall M.A. Ranzinger J. Zeier M. Madhusudhan T. Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair Nucleic Acids Res. 2017 45 10595 10613 10.1093/nar/gkx705 28977635
143. Abe R. Yamagishi S. AGE-RAGE system and carcinogenesis Curr. Pharm. Des. 2008 14 940 945 10.2174/138161208784139765 18473843
144. Derk J. MacLean M. Juranek J. Schmidt A.M. The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration J. Alzheimers Dis. Parkinsonism 2018 8 10.4172/2161-0460.1000421
145. Shaposhnikov M. Proshkina E. Shilova L. Zhavoronkov A. Moskalev A. Lifespan and Stress Resistance in Drosophila with Overexpressed DNA Repair Genes Sci. Rep. 2015 5 15299 10.1038/srep15299 26477511
146. Garinis G.A. van der Horst G.T. Vijg J. Hoeijmakers J.H. DNA damage and ageing: New-age ideas for an age-old problem Nat. Cell Biol. 2008 10 1241 1247 10.1038/ncb1108-1241 18978832
147. Engelman A.N. Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition J. Biol. Chem. 2019 294 15137 15157 10.1074/jbc.REV119.006901 31467082
148. Cherepanov P. LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro Nucleic Acids Res. 2007 35 113 124 10.1093/nar/gkl885 17158150
149. Anisenko A. Kan M. Shadrina O. Brattseva A. Gottikh M. Phosphorylation Targets of DNA-PK and Their Role in HIV-1 Replication Cells 2020 9 1907 10.3390/cells9081907
150. Santos da Silva E. Shanmugapriya S. Malikov V. Gu F. Delaney M.K. Naghavi M.H. HIV-1 capsids mimic a microtubule regulator to coordinate early stages of infection EMBO J. 2020 39 e104870 10.15252/embj.2020104870 32896909
151. De Oliveira D.S. Rosa M.T. Vieira C. Loreto E.L.S. Oxidative and radiation stress induces transposable element transcription in Drosophila melanogaster J. Evol. Biol. 2021 34 628 638 10.1111/jeb.13762 33484011
152. Salces-Ortiz J. Vargas-Chavez C. Guio L. Rech G.E. Gonzalez J. Transposable elements contribute to the genomic response to insecticides in Drosophila melanogaster Philos. Trans. R. Soc. Lond. B Biol. Sci. 2020 375 20190341 10.1098/rstb.2019.0341 32075557

